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ABSTRACT 
Meniere´s disease (MD) is a disorder of the inner ear causing episodic attacks of vertigo, 
hearing loss, and tinnitus. An inner ear magnetic resonance imaging (MRI) method was 
introduced in 2007, which enables the visualization of the endolymphatic hydrops, an 
important pathologic feature of MD. The method is usually performed by applying 
gadolinium-based contrast agents (GBCAs) intratympanically and at significant lower 
doses as compared to the intravenous enhanced doses. The procedure has provided 
important insights into the pathophysiology of MD and has become a standard 
procedure for the diagnosis of the disease. Various GBCAs have been used, but the 
potential toxicities towards sensory hair cells of the inner ear are still poorly understood.  
In the present work a standardized in vivo 24-hour test assay was employed for the 
quantitative assessment of the toxicities of the major GBCAs towards hair cells of the 
lateral line system of Xenopus embryos. After compound treatment, the hair cells were 
stained fluorescently with the dye FM1-43FX and the fluorescence intensity was 
quantitated by fluorescence microscopy. Five commonly used gadolinium-based 
contrast agents, Gadodiamide (Omniscan®), gadobutrol (Gadovist®), gadobenate 
dimeglumine (MultiHance®), gadoterate meglumine (Dotarem®), and gadopentetate 
dimeglumine (Magnograf® or Magnevist®) were assessed. They represent all four 
different types of GBCAs based on the type of ligand (linear or macrocyclic) and charge 
(ionic or non-ionic).  
Dose-response studies were carried out to determine EC50 values (effective 
concentration reducing hair cells staining to 50%) for each GBCA. Free gadolinium 
served as a baseline and was toxic to hair cells with an EC50 of 9.7 µM. By contrast, the 
non-ionic Omniscan and Gadovist displayed no significant hair cell toxicities over the 
entire concentration range (1 – 100 mM) tested. The other GBCAs, all of the ionic class, 
showed increasing hair cell toxicity with relative fluorescence units decreasing below 
75% at 50 mM. Interestingly, MultiHance, and Magnograf were found to be lethal to 
Xenopus embryos at concentrations of 100 mM. Therefore, the potential adverse effects 
of GBCA treatment on Xenopus embryogenesis were investigated in greater detail by 
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monitoring embryos over a five-day period. Free gadolinium caused lethality to 50% of 
the embryos (LC50) at an estimated concentration of 56.7 µM. Embryonic lethality was 
also observed with the ionic MultiHance, Magnograf, and Dotarem, but the estimated 
LC50 values ranged between 50 and 110 mM. By contrast, treatments with the non-ionic 
Omniscan and Gadovist did not interfere with Xenopus embryogenesis even at 100 mM, 
the highest concentration tested. While ionicity was important determinant for hair cell 
toxicity and embryonic lethality of GBCAs, ligand structure (linear or macrocyclic) was 
less critical.   
On the basis of the Xenopus tests, the following conclusions were made. The 
importance of stable chelation of gadolinium was underlined by the high toxicity of free 
gadolinium towards Xenopus embryos and the hair cells of the lateral line. Hair cell 
toxicity of GBCAs, particularly for those of the non-ionic type, was minimal at 
concentrations typically used for intratympanic administration in MD diagnosis, 
suggesting that these GBCAs are safe for MR imaging. The recent European Medicines 
Agency (EMA) recommendations to suspend the use of the linear GBCAs Omniscan, 
MultiHance, and Magnograf, mainly due to the higher risk of retention in human body, 
underlines the importance of low-dose applications as practiced in the intratympanic 
enhanced MRI method. Among the five GBCAs tested in Xenopus embryos, the non-
ionic Omniscan and Gadovist showed the best safety profiles. However, the higher 
deposition-rate of Omniscan in the human body favors the use of Gadovist for 
intratympanic application.  
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ZUSAMMENFASSUNG 
Morbus Ménière ist eine Erkrankung des Innenohrs die Schwindelattacken, Hörverlust 
und Tinnitus verursachen kann. Im Jahre 2007 wurde eine neue Innenohr-MRT-
Methode eingeführt, die es ermöglicht den endolymphatischen Hydrops (EH), eine 
wichtige Pathologie des Morbus Ménière, darzustellen. Bei diesem Verfahren werden 
Gadolinium-basierte Kontrastmittel intratympanal appliziert. Die lokal verstärkte 
Innenohr-MRT hat zu neuen pathophysiologischen Erkenntnissen geführt und ist zu 
einem wichtigen diagnostischen Nachweisverfahren für Morbus Ménière geworden. Es 
werden verschiedene Gadolinium-basierte Kontrastmittel eingesetzt, deren mögliche 
Toxizität für die Haarzellen des Innenohrs jedoch bisher unvollständig untersucht wurde.  
In der vorliegenden Arbeit wurde die Toxizität der wichtigsten Kontrastmittel für die 
Haarzellen der Seitenlinienorgane von Xenopus Embryonen in einem standardisierten in 
vivo 24-Stunden-Testsystem quantitativ untersucht. Dabei werden die Haarzellen von 
behandelten Embryonen mit dem Fluoreszenzfarbstoff FM1-43FX angefärbt und die 
Fluoreszenzintensität mittels Fluoreszenzmikroskopie quantifiziert. Fünf zugelassene 
Gadolinium-enthaltende Kontrastmittel, Gadodiamid (Omniscan®), Gadobutrol 
(Gadovist®), Gadobenat dimeglumin (MultiHance®), Gadoterate meglumin (Dotarem®) 
und Gadopentetat dimeglumin (Magnograf® oder Magnevist®) wurden in Dosis-
Wirkungsstudien eingesetzt um EC50 Werte (effektive Konzentrationen, welche die 
Färbung von Haarzellen um 50% reduzieren) zu ermitteln. Diese fünf Kontrastmittel 
repräsentieren alle vier Gruppen Gadolinium-basierter Kontrastmittel, basierend auf ihrer 
Konfiguration (linear oder makrozyklisch) und Ladung (ionisch oder nicht ionisch). 
Für freies Gadolinium, welches als Ausganssubstanz diente, wurde ein EC50 Wert des 
Haarzellschädigungspotential von 9.7 µM ermittelt. Omniscan und Gadovist zeigten 
hingegen keine signifikante Haarzelltoxizität im gesamten getesteten Bereich von 1 bis 
100 mM. Die anderen Kontrastmittel zeigten eine zunehmende Haarzell-Toxizität mit 
relative Fluoreszenzeinheiten von unter 75% bei Konzentrationen ab 50 mM. Auffällig 
war, dass MultiHance und Magnograf in Konzentrationen von 100 mM letal für Xenopus 
Embryonen waren. Deshalb wurden mögliche schädliche Wirkungen auf die 
Embryonalentwicklung von Xenopus detaillierter untersucht. Kontrastmittel-exponierte 
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Embryonen wurden über einen Zeitraum von fünf Tagen beobachtet. Freies Gadolinium 
war letal für 50 % der Embryonen in einer Konzentration (LC50) von 56.7 µM. Ein 
Ansteigen der embryonalen Letalität wurde auch mit MultiHance, Magnograf und 
Dotarem beobachtet, doch waren die ermittelten LC50 Werte mit 50 und 110 mM massiv 
höher als die für Gadolinium. Eine Exposition mit Omniscan und Gadovist hatte 
hingegen keinen Einfluss auf die Embryonalentwicklung, selbst bei der 
Maximalkonzentration von 100 mM. Während die Ionizität ein wichtiges Merkmal für die 
Haarzell Toxizität und embryonale Letalität der Kontrastmittel war, war die Struktur des 
Liganden (makrozyklisch oder linear) weniger relevant.  
Auf Basis der durchgeführten Xenopus-Experimente konnten folgende 
Schlussfolgerungen gemacht werden. Die Wichtigkeit der stabilen Bindung von 
Gadolinium zu seinem Chelat wurde unterstrichen durch die hohe Toxizität von freien 
Gadolinium für Xenopus Embryonen und die Haarzellen der Seitenlinienorgane. Die 
Haarzelltoxizitäten der geprüften Kontrastmittel war bei Konzentrationen, welche 
typischerweise bei intratympanalen Anwendungen zum Einsatz kommen, 
vernachlässigbar. Dies spricht dafür, dass diese Kontrastmittel sicher sind für den 
Einsatz bei der Innenohr-MRT. Die aktuellen Empfehlungen der European Medicines 
Agency (EMA) den Gebrauch der linear konfigurierten Kontrastmittel Omniscan, 
Magnograf und MultiHance auszusetzten, verdeutlichen die Wichtigkeit geringe Dosen, 
wie sie bei der intratympanal verstärkten Innenohr-MRT Methode zum Einsatz kommen, 
zu verwenden. Omniscan und Gadovist zeigten die besten Sicherheitsprofile unter den 
getesteten Kontrastmitteln. Die höhere Ablagerungsrate von Omniscan im menschlichen 
Körper favorisiert jedoch den Gebrauch von Gadovist für die intratympanale Applikation.  
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1 INTRODUCTION 
Human beings perceive sound and keep balance with help of the inner ear. This vital 
sensory organ is located in a complex cavity in the temporal bone of the skull, known as 
the bony labyrinth. The inner ear is comprised of two functional compartments, the 
cochlea, required for hearing, and the vestibular system, dedicated to balance control. 
Specialized sensory cells, called hair cells, located in these two structures are 
responsible for transduction of motion and sound, respectively. Clinical conditions that 
interfere with inner ear function can cause temporary or chronic symptoms that may 
include hearing impairment, nausea, disorientation, vertigo, and dizziness. In Ménière’s 
disease (MD), patients experience episodes of vertigo, tinnitus, and hearing loss. The 
cause of the disease is unclear and there is currently no cure. Magnetic resonance 
imaging using gadolinium-based contrast agents represents an important tool in the 
diagnosis of the MD. The gadolinium-based contrast agents (GBCAs) used in the 
procedure are considered to be safe, but certain aspects regarding their toxicity towards 
hair cells of the inner ear remain to be elucidated. The present study aims at addressing 
these issues using predictive in vivo tests with embryos and tadpoles of the African 
clawed frog, Xenopus laevis.  
 
1.1 The Inner Ear 
1.1.1 Anatomy 
The human ear is divided into three compartments: the outer ear, the middle ear and the 
inner ear (Schuenke et al., 2010; Snow et al., 2009). The outer ear is the external 
portion of the ear consisting of the cartilaginous auricle and the external auditory canal. 
As shown in Fig. 1, the canal extends internally to the tympanic membrane, where it 
meets the middle ear. This structure consists of the air-filled tympanic cavity and 
includes the tree ossicles (malleus, incus, stapes), stabilizing ligaments, and the 
associated muscles. The Eustachian tube provides a connection between the middle ear 
and the upper throat.   
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Fig. 1. Anatomy of the human middle and inner ear. Figure adapted from (Paulsen and 
Waschke, 2010).  
 
The inner ear consists of the bony labyrinth, which is a system of ducts within the 
petrous part of the temporal bone, and the membranous labyrinth, a similar shaped tube 
system inside the bony labyrinth (Fig. 2). The space between them is filled with a fluid 
called perilymph and is connected to the subarachnoid space via the perilymphatic duct. 
By contrast, the membranous labyrinth is filled with endolymph and has a connection via 
the endolymphatic duct to the endolymphatic sac, an epidural pouch on the surface of 
the temporal bone. The endolymphatic duct widens into a membranous bulb, the 
endolymphatic sinus, and finally opens to the vestibule. The bony labyrinth has two 
membranous windows to the middle ear. The oval window separates the air-filled middle 
ear from the perilymph-filled inner ear and is the contact base to the chain of auditory 
ossicles (Schuenke et al., 2010). The membrane of the round window discloses three 
basic layers: an outer epithelium, a middle core of connective tissue, and an inner 
epithelium (Goycoolea and Lundman, 1997). The inner ear harbors the vestibular 
system and the cochlea, which are connected through the ductus reuniens (Goycoolea 
and Lundman, 1997; Schuenke et al., 2010). 
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Fig. 2. Schematic drawing of the bony and membranous labyrinth comprising the inner 
ear. Figure adapted from (Tillmann, 2010). 
 
1.1.1.1 The auditory apparatus 
The cochlea is a spiral shell-shaped organ that is responsible for mediating auditory 
functions, i.e. the detection of sound waves. It is composed of three fluid-filled ducts or 
scalae (Fig. 3). The scala vestibuli and the scala tympani contain perilymph. The 
cochlear duct, also known as scala media, is filled with the endolymph and harbors the 
central sensory components. It is an extension of the membranous labyrinth and its 
circumference consists of three distinct membranes. The Reissner membrane defines 
the boundary to the scala vestibule. The outer wall of the cochlear duct is known as the 
spiral ligament. It serves as the basement for the stria vascularis, a multilayered organ 
composed of blood vessels and three distinct cell types. The marginal cells line the 
lumen of the scala media. The basal cells are found below the marginal cells, where the 
form a distinct epithelial layer. The intermediate cells are melanocyte-like and contain 
pigments. They are scattered throughout the stria vascularis. Finally, the basilar 
membrane forms the boundary between the cochlear duct and the scala tympani. It 
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serves as a template for the organ of Corti, which harbors the sensory cells of the 
auditory apparatus. The organ of Corti consists of hair cells and supporting cells. The 
hair cells are organized stereotypically into distinct rows. Three rows are occupied by the 
outer hair cells, while the inner hair cells are found in a single row. Hair cells are 
characterized by stereocilia emerging from the apical plasma membrane. They extend to 
the collagenous tectorial membrane and are interlinked by structures known as tip links 
(Schuenke et al., 2010; Schünke, 2011; Snow et al., 2009).  
 
Fig. 3. Crossection of the cochlea illustrating the organ of Corti. The organ of Corti contains 
the sensory hair cells and is exposed to the endolymph of the scala media. Figure adapted from 
(Bley et al., 2015).  
 
1.1.1.2 The vestibular apparatus 
The vestibular labyrinth consists of three semicircular canals and the otolithic organs 
called saccule and utricle. The semicircular canals arise from the utricle and are coated 
by membraneous ducts. The semicircular ducts are organized orthogonally to each other 
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and they harbor ampullae, enlarged areas at one end that contain the sensory hair cells. 
As in the organ of Corti, the hair cells of the vestibular system bear apical stereocilia, but 
in addition they have one long kinocilium. The stereocilia are arranged in order of 
descending length with the kinocilium at one side (Schuenke et al., 2010). The hair cells 
of the ampullae are covered apically by a gelatinous mass, the cupula. The otolithic 
organs are located in the utricle and saccule. Their hair cells are similar to those of the 
ampullae. They are covered apically by a gelatinous extracellular matrix and a layer of 
calcium carbonate crystals, known as statoconia or otholith. Collectively this structure is 
known as the otolithic membrane. The lumen of all sections of the vestibular system is 
filled with endolymph (Purves et al., 2001). 
1.1.2 Physiology 
1.1.2.1 The auditory apparatus 
The inner ear of vertebrates is the sensory organ which is able to perceive auditory and 
vestibular information. Pressure waves let the tympanic membrane, the chain of 
ossicles, and the oval window membrane vibrate. They reach the inner ear through 
transmission of this vibration to the perilymph, the basilar, and tectorial membrane. 
Since the basilar membrane is attached both, medially and laterally, and the tectorial 
membrane only at the spiral limbus, sound waves can deflect the stereocilia by shearing 
forces. Mechanoelectrical transduction (MET) channels located in the wall of the 
stereocilia and tethered to the tip links open or close due to the direction of deflection. 
Unselective cation currents from the endolymph into the hair cells, which are mainly 
borne by potassium and calcium ions, initiate the receptor potential that opens voltage 
gated calcium channels. The calcium ions trigger the basal release of neurotransmitters, 
which bind to the receptors of the corresponding neurons (Fig. 4). The action potentials 
induced in the afferent neurons of the acoustic nerves travel to the brainstem and 
terminate in the auditory cortex (Snow et al., 2009). The outer hair cells amplify the 
tectorial membrane movements by contraction and relaxation, also known as 
electromotility. This amplifying system is only present in mammals and increases the 
hearing sensitivity and sound frequency discrimation (Brownell et al., 1985). Finally, the 
round window bulges out when pressure in the labyrinth rises and it acts as a pressure 
valve (Fettiplace and Kim, 2014; Snow et al., 2009).  
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Fig. 4. Mechanoelectrical transduction in human 
cochlear hair cells. When the tectorial membrane shifts 
against the basilar membrane stereocilia deflect and the 
cation channels open. This leads to a calcium influx via 
voltage gated calcium channels and releases 
neurotransmitters which create the action potential in the 
neuron. Figure adapted from (Lewis and Hudspeth, 1983) 
 
 
 
 
 
1.1.2.2 The vestibular apparatus 
The vestibular system functions together with the proprioceptive and the visual systems 
in the sense of balance and spatial orientation. The semicircular ducts respond to 
angular acceleration, whereas the otolithic organs detect gravity and linear acceleration. 
During angular acceleration of the head, the inertia of the endolymph causes a shift in 
the cupula, which is detected by the hair cells of the sensory epithelium in the ampullae.  
The deflection of stereocilia alters the frequency of neurotransmitter release and the 
induction of action potentials in the afferent vestibular nerve that signals to the vestibular 
nucleus (Schünke, 2011; Snow et al., 2009). The vestibular hair cells are also 
responsible for the vestibulo-ocular reflex, which stabilizes images on the retina during 
head movements by producing compensatory eye movements (Schubert and Minor, 
2004). By contrast, the kinocilia of hair cells located in the otolithic organs sense vertical 
and horizontal head acceleration by detecting inertia of the otoliths (Purves et al., 2001). 
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1.1.2.3 The cochlear fluids 
The maintenance of homeostasis of the cochlear fluids is essential to create electric 
potential differences. The entire epithelium of the cochlear duct is sealed by intercellular 
tight junctions and thereby forms the cochlear “perilymph–endolymph barrier”. While the 
composition of cochlear perilymph resembles that of the extracellular medium, the 
composition of cochlear endolymph is more similar to that of the cytosol (Table 1). With 
an electrode in the scala media a constant direct current of +80 mV, termed 
endocochlear potential, can be recorded at rest, see also Fig. 4 (Eckhard et al., 2014; 
Snow et al., 2009).  
Table 1: Composition of cochlear and related fluids 
 
Cochlear 
Perilymph 
Cochlear 
Endolymph 
Cerebrospinal 
Fluid 
Cytosol 
Na+, mM 148 1.3 149 12 
K+, mM 4.2 157 3 139 
Cl−, mM 119 132 129 4 
HCO3−, mM 21 31 19 12 
Ca2+, mM 1.3 0.023 
 
0.0002 
Protein, mg/ml 178 38 24 100 
pH 7.3 7.5 7.3 7.4 
Table adapted from (Lang et al., 2007) 
The cochlear perilymph has some similarities to the cerebrospinal fluid e.g. high Na+ and 
low K+ concentrations. As mentioned earlier the perilymph is continuous with the 
cerebrospinal fluid via the trabecular meshwork of the perilymphatic duct, but is believed 
to be produced partially by blood ultrafiltration in the stria vascularis (Kellerhals, 1976). 
The K+-rich and Na+-poor endolymph is formed and maintained by the intermediate cells 
of the stria vascularis and by dark cells near the ampullae, both cells types are derived 
from of melanocyte precursors. The endolymph is likely to be absorbed in the 
endolymphatic sac, but there is also evidence suggesting that the endolymphatic sac is 
able to produce endolymph (Kimura, 1967; Rask-Andersen et al., 1999). The 
endolymphatic sinus may also play an important role in volume regulation, as it acts as a 
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mechanical valve to limit endolymph flow to the endolymphatic sac when there is a 
sustained positive pressure in the vestibule (Salt and Rask-Andersen, 2004). Overall, 
ion homeostasis of the different cochlear fluids is essential for the maintenance of the 
different physiological functions of the inner ear.  
 
1.2 Meniere’s Disease 
Meniere´s disease (MD) is a disorder of the inner ear causing episodic attacks of vertigo, 
hearing loss and tinnitus. It has been defined as “the syndrome of endolymphatic 
hydrops” (Monsell et al., 1995). Its accurate diagnosis is difficult and complex. In 
addition, the underlying pathophysiology of the disease is poorly understood. Diagnosis 
and ethology of MD are therefore central issues in MD research. 
1.2.1 History 
The French physician Prosper Ménière described a series of patients with episodic 
vertigo and hearing loss in 1861. Together with the postmortem analysis of a young girl 
who suffered from vertigo after a hemorrhage into the inner ear, vertigo was no longer 
thought to be a cerebral symptom, but could also originate from a pathological process 
in the semicircular canals of the inner ear (Baloh, 2001; Lustig and Lalwani, 1997). 
The Committee on Hearing and Equilibrium formed by the American Academy of 
Otolaryngology and the Head and Neck Surgery Foundation (AAO-HNS CHE) defined 
MD as “recurrent, spontaneous episodic vertigo; hearing loss; aural fullness; and 
tinnitus. Either tinnitus or aural fullness (or both) must be present on the affected side to 
make the diagnosis.” As there is still no final agreement on the pathophysiology, the 
AAO-HNS Committee further stated: “For reporting purposes, Meniere’s disease is a 
clinical disorder defined as the idiopathic syndrome of endolymphatic hydrops.” (Monsell 
et al., 1995).  
1.2.2 Current diagnostic criteria for MD 
In August 2015 a consensus document of the AAO-HNS, the Japanese Society for 
Equilibrium Research, the European Academy of Otology and Neurotology, Bárány 
Society, and the Korean Balance Society stating the diagnostic criteria for MD was 
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published. It contains revised diagnostic criteria and distinguishes between possible, 
probable, definite and certain MD (Lopez-Escamez et al., 2015). 
(i) Possible MD 
Every episodic vertigo or fluctuating hearing loss can be considered as possible MD.  
(ii) Probable MD 
Each of the following three criteria are used to indicate probable MD:  
A. Two or more episodes of vertigo or dizziness, each lasting 20 minutes to 24 hours 
B.  Fluctuating aural symptoms (hearing, tinnitus or fullness) in the affected ear 
C.  Not better accounted for by another vestibular diagnosis 
(iii) Definite MD 
The follow criteria have to be met:  
A. Two or more spontaneous episodes of vertigo, each lasting 20 minutes to 12 hours 
B. Audiometrically documented low- to medium- frequency sensorineural hearing loss 
in the affected ear on at least one occasion before, during or after one of the episodes of 
vertigo  
C.  Fluctuating aural symptoms (hearing, tinnitus or fullness) in the affected ear 
D.  Not better accounted for by another vestibular diagnosis 
(iv) Certain MD 
The diagnosis requires all criteria for definite MD plus a postmortem histopathological 
confirmation of endolymphatic hydrops. 
However, there have been several attempts at defining simple clinical diagnostic criteria 
in the past (Gurkov and Hornibrook, 2018). Each of them has its limitations, including the 
most recent proposal by the Barany Society (Lopez-Escamez et al., 2015). As a 
consequence of the evidence gathered by the morphologic clinical in vivo diagnosis of 
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endolymphatic hydrops, a new terminology has been developed: Hydropic Ear Disease 
(Gurkov et al., 2016). 
1.2.3 Differential Diagnosis 
There are several differential diagnoses to be considered and excluded in the diagnosis 
of MD. These assessments require extensive and time-consuming evaluations, which 
may be perceived as unpleasant by patients. The assessments may include audiometry, 
vestibular evoked myogenic potentials testing, rotatory chair testing, dehydration tests, 
electrocochleography, and video head impulse test. In addition, MRI of the head with an 
intravenous applied contrast agent may be required to exclude oncogenic causes, such 
vestibular schwannoma or endolymphatic sac tumor (Lopez-Escamez et al., 2015; 
Plontke and Gurkov, 2015).  
The differential diagnoses of MD include transient ischemic attack or stroke, since an 
interruption of the blood supply from the vertebro-basilar circulation to the inner ear can 
cause combined audio-vestibular symptoms (Oas and Baloh, 1992), and vestibular 
migraine. The latter manifests with features overlapping with MD, not only in symptoms, 
but also in the histopathology, given that endolymphatic hydrops can be found in many 
cases (Gurkov et al., 2014). Migraine and benign paroxysmal positional vertigo do not 
explain the complete spectrum of MD symptoms and should be considered as co-
morbidities (Lopez-Escamez et al., 2015). Other conditions include monogenetic 
hereditary disease of sensorial hearing loss and further examples listed in Table 2. 
Psychogenic vertigo is also an important differential diagnosis, although it is not 
mentioned in this list. 
Table 2. Differential diagnosis of Meniere’s disease 
Autosomal dominant sensorineural hearing loss type 9  
Autosomal dominant sensorineural hearing loss type 6/14 
Autoimmune inner ear disease 
Cerebrovascular disease (stroke/TIA in the vertebrobasiliar system/bleeding) 
Cogan‘s syndrome. Some cases may have recurrences. 
Endolymphatic sac tumor 
Meningiomas and other masses of the cerebellopontine angle 
Neuroborreliosis 
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Otosyphilis 
Susac syndrome 
Third window syndromes (Perilymph fistula, canal dehiscence, enlarged vestibular aqueduct) 
Vestibular migraine 
Vestibular paroxysmia (neurovascular compression syndrome) 
Vestibular schwannoma 
Vogt-Koyanagi-Harada syndrome 
Table adapted from (Lopez-Escamez et al., 2015) 
1.2.4 Epidemiology 
MD is with a prevalence of about 190-513 per 100.000 one of the most common inner 
ear disorders. It is more common in older female patients of Caucasian background, 
(Alexander and Harris, 2010; Havia et al., 2005; Tyrrell et al., 2014).  
In Caucasian patients, evidence for familial MD is observed in 8-9% of the cases 
examined. Genetic heterogeneity with autosomal dominant inheritance is suspected, but 
clinical differences are currently not obvious (Requena et al., 2014). 
1.2.5 Pathophysiology 
The central and pathognomonic pathology of MD is endolymphatic hydrops (ELH). 
Nevertheless, the etiology of ELH is largely unknown, as are the exact pathophysiologic 
consequences of ELH. Today it is known, that ELH can arise spontaneously (Primary 
Hydropic Ear Disease) or as a consequence of a wide range of serious lesions of the 
inner ear (Secondary Hydropic Ear Disease). The spontaneous remission of rotatory 
vertigo attacks in MD is observed in over 50% of the affected patients within 2 years and 
in over 70% after 8 years. However, many patients are left with poor balance control and 
impaired hearing (Minor et al., 2004).  
ELH is thought to result from the accumulation of the endolymph and alterations of its 
composition in the endolymphatic duct and the vestibular organs. This causes the 
Reissner membrane bulge out and the endolymphatic space is distended into the scala 
vestibuli, affecting mostly the cochlea and sacculus. These effects may also extend to  
the utricle and semicircular canals (Kimura, 1967; Merchant et al., 1995). The degree of 
displacement of the boundary membranes of the endolymphatic space is highest in the 
apex of the cochlea. As a consequence, sound perception is impaired particularly in low 
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to medium frequency range (see also 1.2.2). Rupture of the membranes may cause 
acute vertigo, tinnitus, and hearing loss attacks, probably by causing electrolyte 
intermixture (Salt and Plontke, 2010). In humans, the ELH can occur idiopathic or be 
caused by specific disorders e.g. infectious labyrinthitis, noise induced hearing loss, or 
vestibular schwannoma (Plontke and Gurkov, 2015). 
The development of an ELH in MD is thought to be caused by either by (i) a decrease in 
endolymph drainage, or (ii) an increase in endolymph production. 
As mentioned earlier, the endolymphatic sinus is believed to act as one-way valve. It 
either allows the flow of the endolymph to the endolymphatic sac or prevents it. Hence, 
dysregulation could lead to hydrops formation (Salt and Rask-Andersen, 2004). In 
addition, destruction or any occlusion of the endolymphatic sac can cause accumulation 
of the endolymph (Kimura, 1967). Finally, the endolymphatic sac function can be altered 
by medication. For example, systemic catecholamines will cause an increase of the 
endolymphatic pressure (Inamoto et al., 2009).  
With regard to mechanisms influencing endolymph production, changes in the ion 
composition of the endolymph can become osmotically relevant and induce volume 
expansion. Furthermore, longitudinal endolymph flows mediated by water permeation 
between the endolymph and perilymph via aqueous pores could contribute to ELH  
formation (Eckhard et al., 2014). 
Importantly, postmortem histopathological analysis of the inner ear of patients diagnosed 
with definite MD has demonstrated the presence of ELH in nearly all cases studied. At 
present, the thesis that MD causes the development of ELH or that it is an 
epiphenomenon cannot be supported. The ELH appears to be necessary but not 
sufficient for MD manifestation. Vascular risk factors should be considered as possible 
cofactors (Foster and Breeze, 2013; Rauch et al., 1989). In summary, it is clear that 
further research in needed to clarify these issues. The recent development of MR 
imaging of the endolymphatic and perilymphatic space may contributed to novel insights 
and a better understanding of the pathophysiology of MD, as discussed in section 1.5. 
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1.3 Xenopus, a Versatile Vertebrate Model Organism 
for Biomedical Research 
The clawed frogs of the Xenopus genus are aquatic frogs and belong to the Pipidae 
family of amphibians. The model organism Xenopus includes the species Xenopus 
laevis and Xenopus tropicalis, whose genomes are fully sequenced (Session et al. 
2016). Xenopus laevis has been widely used for genetic, embryonic, and 
electrophysiological research, as well as for a historic pregnancy test (Hobson, 1958; 
James-Zorn et al., 2018; Sater and Moody, 2017). More recently, its value in drug 
discovery and development including drug target identification, lead compound 
discovery, and assessment of drug toxicity has been recognized (Wheeler and Brandli, 
2009). As an amphibian, Xenopus frogs are evolutionary closer related to humans than 
for example fish. The latter have diverged about 455 million years ago from vertebrate 
evolution leading to modern-day mammals, while amphibians have done so an 
estimated 360 million years ago (Schmitt et al., 2014).  
Since Xenopus frogs are obligatory aquatic, they can be easily housed in aquaria and 
do not require terraria. Minced meat or food pellets are sufficient for feeding the adults 
(Schmitt et al., 2014). Female frogs lay hundreds of eggs at one time, which can be 
fertilized in vitro permitting the generation of many embryos undergoing synchronous 
development (Wallingford et al., 2010). The embryos become transparent as 
development proceeds. The tadpole are robust in handling, develop fast, and show 
many morphological similarities the mammalian counterparts (Fig. 5). The skin is 
permeable to small organic molecules, which has been beneficial for drug screening and 
testing (Schmitt et al., 2014; Wallingford et al., 2010).  
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Fig. 5. The Xenopus animal model. A: Adult female Xenopus laevis frog. B: Xenopus laevis 
embryo at stage 41. Important organs of vertebrate organisms are indicated. Figures adapted 
from (Schmitt et al., 2014).  
1.3.1 Anatomy and Development 
The development of Xenopus laevis was systematically surveyed and described by 
Nieuwkoop and Faber in 1956. They defined 66 developmental stages from oocyte to 
the end of metamorphosis according to external and internal morphological criteria 
(Nieuwkoop and Faber, 1967). The fertilized egg (stage 1) of the poikilothermic Xenopus 
laevis frog develops temperature-dependent (Fig. 6). At 23 °C, the first cleavage division 
can be observed after 90 min (stage 2). The next eleven cleavages occur every 30 min. 
Yolk platelets are early consumed and the embryo becomes transparent quickly. 
Gastrulation, neurulation and the onset of the organogenesis continue to happen within 
48-72 hours. The key organs of vertebrate body are established during the 
organogenesis period. This includes the cardiovascular system, the lymphatic 
vasculature, the digestive tract, excretory organs, the hematopoietic system, the central 
nervous system, eyes, the olfactory system, the inner ear with cochlear and vestibular 
organs, and the lateral line system (Fig. 5). Eight to twelve weeks after fertilization, 
metamorphosis sets in to transform the tadpole to an adult frog, which includes the 
development of limps and lungs. Unlike most other frog species, Xenopus remains full 
aquatic throughout adult life (Schmitt et al., 2014). Given the anatomical and histological 
similarities, hair cells of the lateral line can be used to assess the toxicity of substance 
that may be ototoxic (see 1.5. for details).  
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Fig. 6. The life cycle of 
Xenopus laevis. Major 
steps in development of 
Xenopus individuals are 
illustrated. The time 
specifications refer to 
development at 23°C. 
Adapted from (Schmitt et 
al., 2014).  
 
1.3.1.1 The lateral line system 
The lateral line system is a sensory organ found in larval stages of fish and amphibians, 
and persist into adulthood in fish and aquatic amphibian. It is located in the epidermis of 
the body, where it functions in the detection of water flow. Therefore, it plays an 
imported role in  feeding, swimming, navigation and communication behaviors (Coombs 
et al., 2013). In amphibians, cranial ectodermal sensory placodes migrate during 
embryogenesis along the head and trunk to form characteristic lines of differentiating, 
superficial neuromasts (Fig. 7). Each organ consist of a functional unit comprised of 
mechanosensitive hair cells,  which share many morphological and functional similarities 
with the hair cells of the mammalian inner ear. Hair cells of the lateral line and the inner 
ear are probably derived from an evolutionary related sensory placode (Baker, 2008; 
Kalmijn, 1989). The hair cells extend into one kinocillium and a bundle of linked 
stereocilia. They are embedded in a gelatinous cupula, which is secreted by supporting 
cells (Baker, 2008). Water flow induced drag forces deflect the cilia. This creates an 
electric potential that travels via the afferent fibers to the hindbrain. The efferent 
innervation suppresses self-stimulation from self-movements and -vocalization (Baker, 
2008).  
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Fig. 7. The lateral line system. A: Schematic illustration of superficial neuromast of the lateral 
line. Each neuromast of the lateral line contains several hair cells, support and mantle cells. The 
green illustrated hair cells cilia are embedded in the gelatinous cupula. Figure adapted from 
(Chiu et al., 2008). B: Xenopus embryo at stage 45 (bright field image). C: Fluorescence image 
of the same embryo displaying fluorescently stained lateral line organs. The staining in 
developing gut is results from auto-fluorescing yolk platelets.  
 
 
1.4 Gadolinium-based Contrast Agents 
1.4.1 Gadolinium 
Gadolinium is a naturally occurring chemical element with the atomic number 64. It is 
rare-earth heavy metals of the lanthanide group with strong paramagnetic properties. Its 
trivalent ions, gadolinium (III) (Gd3+), have seven unpaired electron spins, which are 
responsible for its enormous paramagnetic properties above 20°C with strong relaxation 
effects. Given these unique physical properties, gadolinium has become a major 
constituent of contrast agents for MRI. Free Gd3+ is however highly toxic as it has a 
similar ionic radius compared with Ca2+. As demonstrated in animal studies, Gd3+ 
competes with Ca2+ ions and, as a trivalent ion, it binds with higher affinity to target 
proteins (Sherry et al., 2009). The median lethal dose (LD50) for intravenously 
administered Gadolinium in rats has been estimated at 0.5 mmol/kg (Gries, 2002). To 
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avoid the toxicity of free Gd3+, the cation is always chelated with 
polyaminopolycarboxylic acids that serve as ligands. In addition, chelation also 
preserves the paramagnetic properties of Gd3+. Nevertheless, Gd3+ can also be set free 
despite chelation. For example, endogenous anions may have higher affinity for 
gadolinium ions than the ligand. Alternatively, endogenous cations may compete with 
gadolinium for binding to the ligand (Ramalho et al., 2016). This exchange process is 
known as transmetallation (Haley, 1965; Hirano and Suzuki, 1996; Sherry et al., 2009). 
Possible toxic effects of free gadolinium ions include the induction of apoptosis, the 
release of chemokines, and increased oxidative stress (Rogosnitzky and Branch, 2016).  
Importantly, gadolinium ions are able to block various mechanically gated channels, 
such as baroreceptors that sense pressure changes in rats (Kraske et al., 1998). Yang 
and Sachs used Xenopus oocytes expressing stretch-activated channels to study the 
effects of gadolinium (Yang and Sachs, 1989). They found a concentration-dependent 
block of channel opening after gadolinium treatment.  
At a gadolinium concentration of 5 µM the probability of a channel being open was about 
10-1, whereas at 10 µM the value dropped to less than 10-5 (Yang and Sachs, 1989). 
Studies across different model organisms provide compelling evidence that gadolinium 
ions have toxic effects on hair cells of the inner ear by interfering with MET channel 
functions. Cochlear hair cells of chicken, turtles, and guinea pigs were found to be 
susceptible to gadolinium-induced toxicity resulting in the blocking of MET currents 
(Farris et al., 2004; Kimitsuki et al., 1996; Santos-Sacchi, 1991). Expression of the 
transient receptor potential channel vanilloid subfamily member 4 (TRPV4) is associated 
with inner and outer hair cells, supporting cells, and marginal cells of the inner ear 
(Takumida et al., 2005). Since gadolinium can block TRPV4 functions (Andrade Yé et 
al., 2005), TRPV4 might mediate some of the toxic effects of free gadolinium ions on 
hair cells of the inner ear. As outlined below, the toxic effects of free gadolinium extend 
beyond the inner ear (see 1.4.2.2.). Taken together, the safe application of gadolinium in 
contrast agent for MRI requires its stable ligation to a carrier molecule in order to 
minimize the toxic effects of free gadolinium ions.  
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1.4.2 Gadolinium-based Contrast Agents for MRI 
Several metal ion chelates were developed over the last 30 years to overcome the 
toxicity of free gadolinium ions (Runge et al., 2011). These chelates differ in their 
biodistribution, which is useful for specific applications of GBCAs. When injected 
intravenously, GBCAs rapidly equilibrate in the intravascular and extracellular 
compartment. The biological elimination half-life is about 1.5 - 2.0 hours in patients with 
normal renal function (Bellin and Van Der Molen, 2008). GBCA indications include the 
contrast imaging of vessels by MR angiography or the imaging of pathological processes 
in the central nervous system, mainly tumors, with GBCAs that penetrate the blood-brain 
barrier (Runge et al., 2011). The five GBCAs that were examined in the present study 
are classified as extracellular fluid agents or intravenous contrast agents. They are 
approved for human applications by the European Medicines Agency (EMA) and the 
U.S. Food and Drug Administration (FDA). Their chemical structures are shown in Fig. 8. 
They represent examples of the major subclasses of GBCAs. In the context of the 
present work, brand names will be used in place of the compound names (see Table 3) 
enabling the reader to better distinguish the different GBCAs.  
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Fig. 8. Chemical structures of selected GBCAs. All GBCAs depicted consist of ligands that 
enable 8-coordinate binding to gadolinium. In each case, there is a single water molecule bound 
to gadolinium. The GBCAs shown are examples of non-ionic (A) and ionic linear ligands (B, C) 
as well as ionic (D) and non-ionic macrocyclic ligands. Figure adapted from (Aime and Caravan, 
2009). 
1.4.2.1 Classification and chemical properties of GBCAs 
There are four different classes of GBCAs based on the type of the ligand structure 
(macrocyclic or linear) and its charge (ionic or non-ionic) (Idée et al., 2014; Sherry et al., 
2009). Macrocyclic ligands fully capture the gadolinium ion in a preorganized cubic 
cavity, whereas linear ligands bind the ion using an open-chain structure. Regarding 
ionic GBCAs, they harbor counterions bound via ionic bonds to the ligand that dissociate 
in water and increase the osmolality. The presence of counterions can contribute to the 
toxicity of GBCAs (Kun and Jakubowski, 2012). The differences in the chemical 
structures impact the kinetic and thermodynamic stability of GBCAs. In an assessment 
of complex stability under conditions similar to those in the human body, ionic 
macrocyclic GBCAs showed the highest stability, followed by the ionic linear ones, 
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whereas the nonionic linear chelates released gadolinium the most (Frenzel et al., 2008) 
(Sherry et al. 2009). Key physiochemical characteristics of the five GBCAs studied in the 
present work are summarized in Table 3. All five GBCAs are eliminated by renal 
filtration, except from MultiHance. The latter contains a benzyl group (Fig. 8) enabling 
hepatic uptake and clearance (Aime and Caravan, 2009). The recommended standard 
dosing of GBCAs is 0.1 mmol/kg, but this may change depending on the specific 
indication and vary from country to country (Aime and Caravan, 2009; Runge et al., 
2011). The equilibrium process of dissociation of gadolinium and the chelate can be 
measured by applying heat. The thermodynamic constant is determined at pH 1, 
whereas the conditional stability constant is measured at pH of 7.4, which is more 
appropriate when considering the in vivo situation, The higher these constants are, the 
more energy is needed to release gadolinium from the chelate (Ramalho et al., 2016). 
Kinetic stability represents an alternative approach to assess GBCA stability. It refers to 
the dissociation half-life at pH 1 and 25°C (Port et al., 2008). The solubility of an organic 
compound in aqueous solutions is determined by its hydrophilicity. One measure of 
hydrophilicity is the logP value, which is defined as the ratio of the concentrations of the 
test compound in a mixture of two immiscible phases (octanol and water) at equilibrium. 
Hydrophilic substances carry negative logP values. 
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Table 3. Characteristics of GBCAs 
Brand 
Name 
Omniscan Magnograf MultiHance Dotarem Gadovist 
Generic 
Name 
Gadodiamide Gadopentetate-
dimeglumine 
Gadobenate-
dimeglumine 
Gadoterate-
meglumine 
Gadobutrol 
Acronym Gd-DTPA-
BMA 
Gd-DTPA Gd-BOPTA Gd-DOTA Gd-DO3A-
Butrol 
Manufactur
er  
GEHealthcare Bayer Bracco  Guerbet Bayer 
Ligand 
Type 
Linear Linear Linear Macrocyclic Macrocyclic 
Ionicity Non-ionic Ionic Ionic Ionic Non-ionic 
Clearence Renal Renal Renal (96%) 
Hepatic (4%) 
Renal Renal 
Dosing 
(mmol/kg) 
0.1 0.1 0.05 - 0.1 0.1 - 0.2 0.1 
Osmolarity
(Osm/kg 
H2O, 37°C) 
0.79 1.96 1.97 1.37 1.60 
logKtherm 16.9 22.1 22.6 25.6 21.8 
logKcond 14.9 17.7 18.4 19.3 14.7 
T1/2  > 5 sec > 5 sec > 5 sec 338 hours 43 hours 
logP 
(octanol: 
water) 
- 2.13 - 3.16 - 2.33 - 2.87 - 2.0 
Molecular 
mass 
(g/mol) 
592 938 1058 754 605 
Abbreviations: Ktherm, thermodynamic stability constant; Kcond., conditional stability constant; T1/2, 
dissociation half-time at pH 1.0 and 25°C. Table contains data taken from published sources 
(Runge et al., 2011) (Idée et al., 2014) (Bennett et al., 2012). 
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1.5 Magnetic Resonance Imaging of the Inner Ear 
In the past decade, advances in MRI of the inner ear, particularly the ability to 
discriminate between the perilymphatic and endolymphatic spaces, have been key for 
the diagnosis and the characterization of the pathology of diseases associated with ELH.  
The importance of MRI for the differential diagnosis of MD and vestibular migraine has 
been reviewed recently (Gurkov et al., 2014). The key findings regarding MD’s 
pathophysiology obtained by MRI include that (i) the cochlear and vestibular labyrinths 
can be differently affected; (ii) the degree of ELH correlates with duration and degree of 
symptoms, and (iii) the clinically asymptomatic contralateral ear often contains also an 
ELH, suggesting MD is a systemic disease (Gurkov et al., 2016; Plontke and Gurkov, 
2015; Pyykko et al., 2013). Visualization of ELH by MRI can be performed by two distinct 
approaches that rely on applying the GBCAs either (a) intratympanically or (b) 
intravenously as detailed below.  
1.5.1 Intratympanic Enhanced Inner Ear MRI  
The first successful visualization of ELH in humans was achieved by three-dimensional 
fluid attenuated inversion recovery (3D-FLAIR) MRI at 3 Tesla (3T)  after intratympanic 
application of gadolinium hydrate (Nakashima et al., 2007). The method was 
subsequently improved by employing the 3D inversion-recovery turbo spin echo (3D-IR 
TSE) sequence (Naganawa et al., 2008). This modification permitted not only the 
imaging of the endolymphatic and the perilymphatic space, but also the surrounding 
bone structures could be visualized (Fig. 9).  
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Fig. 9. Axial 3D-IR TSE MRI of the left inner ear. A: Healthy left inner ear, no evidence for EH; 
B: marked EH, the hypointense areas correlate with the enlarged, out bulging endolymphatic 
space. Figure adapted from (Gurkov et al., 2012). 
After intratympanic application of GBCAs, the agent appears to selectively enter the 
perilymphatic compartment by diffusion mainly via the oval, but also via the round 
window (Zou et al., 2012). However, GBCA uptake into the inner ear has been reported 
to be insufficient in five to ten percent of the treated patients (Gurkov et al., 2016).  
Intratympanic enhanced MRI was also found to be helpful in predicting the ability of 
intratympanically injected drugs, such as steroids and gentamicin used to treat MD, to 
diffuse in the inner ear (Yamazaki et al., 2012). It should be emphasized that the 
intratympanic use of GBCAs is currently still off-label.  
1.5.1.1 Intratympanic GBCA-enhanced inner ear MRI 
Standardized approaches for intratympanic GBCA injection followed by MRI are 
currently in development. An example of a currently used protocol is described next. 20 - 
28 hours before MRI, the external auditory canal is cleaned. The procedure is initiated 
anesthetizing the tympanic membrane with 4% tetracaine. Subsequently, the 0.5 mM 
GBCA stock is diluted eightfold with physiological saline to a final concentration of 62.5 
mM.  0.4 ml of the diluted GBCA solution is injected under microscopic control into the 
middle ear. After the injection, the patient will be put into the supine position (lying 
horizontally with the face and torso facing up). The head will be turned 45° to the 
opposite side for 30 min without speaking or swallowing to allow the GBCA to diffuse 
into the inner ear prior to MRI (Bykowski et al., 2015; Gurkov et al., 2016). Various 
combinations of scanners and coil models/channels have been utilized for the detection 
of ELH by GBCA-enhanced MRI. A field strength of 3 Tesla is generally required 
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(Gurkov et al., 2016). To date, the best image quality is achieved using a hybrid of 16-ch 
head coil and ear coil (loop 7 cm) (Zou J, 2015). Furthermore, computer-aided 
segmentation of endo- and perilymphatic spaces was developed to evaluate the 
obtained MR images in a quantitative and observer-independent manner (Zou J, 2015). 
1.5.2 Intravenous GBCA-enhanced Inner Ear MRI 
Intravenous injection of GBCAs represents an alternative method for inner ear MR that 
permits the discrimination between the perilymphatic and endolymphatic spaces. This 
second method relies on the observation that the blood-perilymph barrier is not as tight 
and impenetrable as the blood-endolymph barrier (Zou et al., 2009). For many years, the 
required intravenous doses of GBCAs that would enable sufficient GBCA delivery to the 
perilymph were considered too high and not tolerable. For this reason, the intratympanic 
GBCA application was initially favored and investigated in detail. In 2010, however, the 
first successful visualization of ELH after intravenous administered GBCAs was reported 
(Nakashima et al., 2010). Specifically, a doubling of the GBCA dose to 0.2 mmol/kg was 
required and the perilymph signal intensity was lower compared to intratympanic GBCA 
applications. Subsequently, further improvements in MRI technology allowed for a 50% 
reduction of the GBCA dose (Naganawa et al., 2012). Specifically, the improved protocol 
uses a standard dose of GBCA (Omniscan, 0.1 mmol/kg), which is injected 
intravenously four hours prior to MRI. A 3T MR subtraction technique, known  
HYDROPS2 (hybrid of reversed image of MR cisternography and positive perilymph 
signal by heavily T2- weighted 3D-FLAIR) was employed to visualize ELH (Naganawa et 
al., 2012). 
1.5.3 Comparison between Intratympanic and Intravenous GBCA-enhanced Inner 
Ear MRI 
The advantages and disadvantages of the two GBCA-enhanced inner ear MRI methods 
are summarized in Table 3. Importantly, systemic adverse side effects are more likely to 
occur after intravenous than intratympanic GBCA administration given the much higher 
dose of GBCA required, 7 mmol vs. 0.025 mmol, respectively (see below for details). 
Irrespective of the administration method used, GBCAs may reach the hair cells in the 
endolymphatic compartment raising the possibility of GBCA-induced ototoxicity. To date, 
this notion could however not been corroborated in experimental studies using guinea 
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pigs or mice (Counter et al., 2000) (Counter et al., 2013). For example, high resolution 
images of strong field (9.4 T) MRI in mice could not detect a GBCA-increased signal 
intensity in the endolymph, when applied intravenously (Counter et al., 2013). 
Furthermore, a comparison of the two GBCA application methods by inner ear MRI in 
mice revealed no differences in GBCA permeation into endolymph (Zou et al., 2010). 
More recently, first studies using a combination of an intravenous and intratympanic 
GBCA injections have provided promising results warranting more detailed  investigation 
(Iida et al., 2013; Naganawa et al., 2014). According to our clinical experience, 
intratympanic contrast application has a greater ability to detect mild ELH than 
intravenous contrast application, due to its stronger signal-to-noise ratio (Plontke and 
Gurkov, 2015). It should further  be kept in mind that the total dose in the intratympanic 
route is about 500-fold lower than in the intravenous route. 
Table 3. Comparison of intratympanic and intravenous GBCA-enhanced inner ear 
MRI 
 Intratympanic Method Intravenous Method References 
Signal intensity in 
perilymph 
Higher Lower (Nakashima et al., 
2010; Yamazaki et 
al., 2012) 
Total GBCA dose Lower (~ 0.025 mmol) Higher (~ 7 mmol) (Gurkov et al., 
2016) 
Average success 
rate (Causes of 
failure) 
90% - 95% (insufficient 
GBCA uptake into 
perilymph) 
95% (claustrophobia, 
gross motion, metal 
artifact) 
(Gurkov et al., 
2016; Naganawa 
and Nakashima, 
2014) 
Waiting time  24 hours 4 hours (Gurkov et al., 
2016; Naganawa et 
al., 2012) 
Potential ASE  Primarily local Systemic  
 
1.6 Toxicity of GBCAs  
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GBCAs used at the recommended doses for MRI were initially considered to be 
relatively nontoxic for the human body. In the last decade, however, reports about 
severe adverse effects, mostly in patients with reduced renal function, have begun to 
emerge. In patients with renal insufficiency, renal elimination of GBCAs is reduced, 
gadolinium ions dissociate from the chelate, and they accumulate in the body, where 
they initiate a specific type of fibrosis, termed nephrogenic systemic fibrosis (NSF). The 
symptoms of NSF range from erythema, subcutaneous nodules in the skin, over painful 
muscle and joint contractions with reduced mobility to fibrosis of inner organs like lung, 
heart, and liver. The diagnosis is mostly made by taking a skin biopsy. The prognosis is 
at present unfavorable as there are still no effective treatment options (Cheong and 
Muthupillai, 2010; Grobner, 2006; Rogosnitzky and Branch, 2016). The estimated 
incidence of NSF (for the period from 2003 to 2006) is at 36.5 cases per 100’000 GBCA 
administrations (Perez-Rodriguez et al., 2009). In 2006, the FDA and the EMA issued 
alerts regarding the use of GBCAs in patients with renal insufficiency. The administration 
recommendations for GBCAs were subsequently modified, which led to a considerable 
decrease of new NSF cases (Bennett et al., 2012; EMA, 2010; FDA, 2006).  
In the past two years, however, several new studies appeared, which provide evidence 
that gadolinium accumulates in the brain, bone, and kidneys of patients who were 
exposed to GBCAs, regardless of their renal function (Kanda et al., 2015; McDonald et 
al., 2017; Ramalho et al., 2016; Rogosnitzky and Branch, 2016). It is still not known 
whether it accumulates in its free or chelated form (Rogosnitzky and Branch, 2016). 
Besides NSF, GBCA administration was also found to cause acute, for instance nausea 
or anaphylaxia, and chronic or delayed adverse side effects. Table 4 provides an 
overview of reported adverse side effects not related to NSF observed after GBCA 
exposure in patients and model systems.  
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Table 4. GBCA-induced toxicity endpoints 
Toxicity endpoints Study type Species/cells Reference 
Necrosis and apoptosis In vitro Renal tubular 
cells 
(Heinrich et al., 
2007) 
Nephrotoxicity (reduced glomerular 
filtration rate) 
In vivo Pigs (Elmstahl et 
al., 2006) 
Nephrotoxicity (acute tubular necrosis) Case report Human (Akgun et al., 
2006) 
Hematoxicity (reduced WBC count) 
Hepatotoxicity (vacuolar degeneration, 
disorganized hepatic cords) 
In vivo Mice (Chen et al., 
2015) 
Pancreatitis Case report Human (Blasco-Perrin 
et al., 2013) 
Neurotoxicity (myoclonus, ataxia, 
tremor, and corpus callosum damage 
and hemorrhage) 
In vivo Rats (Ray et al., 
1996) 
Neurotoxicity (encephalopathy) Case report Human (Hui and 
Mullins, 2009) 
WBC: White blood count. Table adapted from (Rogosnitzky and Branch, 2016) 
1.6.1 GBCAs toxicity to the inner ear 
Intratympanic application of GBCAs has been used as a standard procedure for the 
diagnosis of Meniere’s diseases, see section 1.5.1.1. This raises the question whether 
there is a risk for GBCA-induced ototoxicity in patients exposed to GBCAs. Several in 
vivo and in vitro testing models have been used to characterize the effects of GBCAs on 
the inner ear, especially the sensory hair cells. 
Effects on the stria vascularis 
Intratympanic administration of eightfold diluted Omniscan had no toxic influence on the 
stria vascularis of the inner ear in guinea pigs. A higher concentration decreased the 
endocochlear potential and affected the marginal cells of the stria vascularis (Kakigi et 
al., 2008). In a separate study, Omniscan and Magnograf (also known as Magnevist) 
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were placed on the round window of guinea pig inner ears. Using electron microscopy, 
no alterations were observed in the stria vascularis (Suzuki et al., 2011).  
Effects on hair cells of the inner ear 
After intratympanic application of Omniscan in mice, mild hearing loss was detected 
using auditory brainstem response technique, while ProHance had no adverse effects in 
the same experiments (Nonoyama et al., 2016). In guinea pigs, no significant decrease 
in auditory brainstem response measurements was observed in experiments, where 
Omniscan was applied to the round window membrane of the inner ear (Duan et al., 
2004). Similar results were obtained in an independent study (Zou et al., 2009). Using  
outer hair cells isolated from guinea pigs, a moderate morphological damage was found 
in 24% of the cells after administration of eightfold-diluted  and in 3% of the cells with a 
sixteen-fold diluted ProHance®, a nonionic macrocyclic GBCA (Katahira et al., 2013).  
In a study using isolated vestibular hair cells from bullfrogs, application of a four to 
sixteen-fold dilution of Omniscan led to morphological damage and reduced the 
frequency of action potentials in the semicircular canals, while 32-fold diluted Omniscan 
produced no obvious changes (Tanaka et al., 2010). 
In 2007, Nakashima et al. succeed in visualizing ELH with three-dimensional fluid 
attenuated inversion recovery (3D-FLAIR) MRI in patients after intratympanic application 
of Omniscan. The authors did not report any adverse effects (Nakashima et al., 2007). 
Similarly, evaluation of treated patients failed detect any hearing loss one day after 
intratympanic administration of Magnograf (Louza et al., 2012). In a separate study with 
65 MD patients, where the observation time was increased to one week, again no 
effects on audiologic control could be detected (Louza et al., 2013). Finally, a long term 
study with a follow-up at least six months after treatment showed no evidence of 
ototoxicity of intratympanic GBCA injection (Louza et al., 2015). Furthermore, to the best 
of our knowledge, there has been no report of GBCA-related intratympanic ototoxicity in 
the literature to date. Table 5 summarizes the key findings of the studies assessing 
ototoxicity mentioned above. Overall, the present evidence indicates little or no effects of 
intratympanic GBCA on hair cells of the inner ear. It is however not known, if all GBCAs 
have low ototoxicity.  
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Table 5. Selected studies assessing ototoxicity of GBCA exposure 
Species Compound Dilution Methodology Toxic effects Reference 
Guinea pig Omniscan 1 ABR None  (Duan et al., 
2004) 
 Omniscan 1 ABR None  (Zou et al., 
2009) 
 Omniscan, 
Magnevist 
(Magnograf) 
1/8 Electron 
microscopy 
None  (Suzuki et 
al., 2011) 
 ProHance 1/8 - 
1/16 
OAE (distortion 
product evoked) 
microscopy 
Moderate 
morphological 
damage 
(Katahira et 
al., 2013) 
Mouse Omniscan, 
ProHance 
1 ABR Significant 
threshold 
decrease at 8 kHz 
with Omniscan; 
None observed 
with ProHance 
(Nonoyama 
et al., 2016) 
Bullfrog Omniscan  1/4 - 
1/32 
AP recording 
after stimulation, 
Microscopy 
Concentration-
dependent 
morphological and 
physiological 
damages 
(Tanaka et 
al., 2010) 
Human Omniscan 1/8  None (Nakashima 
et al., 2007) 
 Omniscan 1/8 Audiometry None (Louza et al., 
2012) 
 Omniscan 1/8 Audiometry None (Louza et al., 
2013) 
 Magnograf 1/8 Audiometry None (Louza et al., 
2015) 
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Abbrevations: ABR, auditory brainstem response; AP, action potential; OAE, otoacoustic 
emissions. None indicates that no adverse side effects were observed.  
 
1.7 Gentamicin and Its Application in MD Treatment 
Gentamicin is a common aminocyclitol-aminoglycoside antibiotic with good effectiveness 
in gram-negative bacteria, but also in Staphylococcus and Mycobacterium tuberculosis. 
However, it can cause severe adverse side effects, mainly oto- and nephrotoxicity 
(Appel and Neu, 1978). The hearing damage is irreversible and it affects selectively the 
hair cells of the inner ear, most likely due to the high potential difference between the 
endolymph and these cells (Chen et al., 2014). Intratympanically applied gentamicin can 
destroy hair cells by diffusion via the round and oval window and is an ablative treatment 
method for a long-term control of vertigo in unilateral MD (Hsieh et al., 2009; Plontke et 
al., 2002). Due to the observed predilection of vestibulotoxicity over cochleotoxicity when 
applying Gentamicin, the vertigo can be reduced while hearing loss can be prevented in 
most cases (Plontke and Gurkov, 2015; Pullens and van Benthem, 2011).  
 
1.8. Assessing Hair Cell Toxicity in Xenopus Embryos 
In the present work, hair cells of the lateral line system of Xenopus embryos will be used 
to assess the potential ototoxicity of various GBCAs in vivo. The aminoglycoside 
antibiotic gentamicin will serve as a positive control, given its known toxicity to hair cells 
of the inner ear and the lateral line system. For example, the hair cell toxicity of 
gentamicin was assessed in Xenopus embryos by Stefan Schmitt in our laboratory in the 
context of his PhD thesis (Schmitt et al., manuscript in preparation). Toxic effects of drug 
treatment on hair cells of the lateral line system can be visualized and quantitated by 
fluorescent microscopy. For this purpose, styryl pyridinium dyes such as FM1-43FX or 
DASPEI/DAPI are used to stain hair cells in the lateral line systems of zebrafish and 
Xenopus (Cochilla et al., 1999; Gale et al., 2001; Stengel et al., 2017)). Our laboratory 
found FM1-43FX to suit best for quantitatively measuring drug effects on hairs cells, as it 
features enormous staining ability and high selectivity (Schmitt et al., manuscript in 
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preparation). FM1-43FX is a non-toxic water-soluble styryl pyridinium dye, which is 
unable to penetrate the lipid bilayer of membrane cells. It enters selectively hair cells by 
diffusion via the MET channels at the tips of the stereocilia and labels endosomes, 
mitochondria and rough endoplasmatic reticulum (Gale et al., 2001; Meyers et al., 2003; 
Nishikawa and Sasaki, 1996). The aliphatic amine group allows for aldehyde-based 
fixation through crosslinking, e.g. with formaldehyde (Fig. 10). Using FM1-43FX to stain 
hair cells of the lateral line system after GBCA treatment, the in vivo toxicity of GBCAs 
will be established in a comparative manner under established standard conditions.  
 
 
Fig. 10. Structure of FM1-43FX. The fluorescent dye FM1-43FX, ((n-(3-
aminopropyldiethylammoniumpropyl)-4-(dibutylamino)-styryl) pyridinium tri-chloride, contains a 
fluorescent styrylpyridinium moiety (right) and an aliphatic amine group (left). 
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2 AIMS OF THE STUDY 
The general goal of the present study was the assessment of the safety of GBCAs for 
hair cells, which are the sensory cells of the auditory and vestibular organs of the body. 
Five compounds representing four distinct classes of GBCAs were selected for 
comparative characterization. In vivo toxicity testing was performed using the hair cells 
of the lateral line system of the Xenopus embryo. Using a standardized in vivo test 
system, the following specific aims were defined:  
- To carry out dose-dependent treatments of Xenopus embryos with waterborne 
GBCAs and monitor their effects on hair cells of the lateral line system 
- To establish quantitative hair cell toxicity parameters, i.e. EC50 values 
- To assess the overall toxicities of GBCAs for Xenopus embryos, i.e. LC50 values 
- To compare the hair cell toxicity parameters established for GBCAs in Xenopus 
with those determined using other animal models and in human patient studies 
- To formulate recommendations regarding the safety of GBCAs for intratympanic 
applications 
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3 MATERIALS AND METHODS 
3.1 In vitro Fertilization and Culture of Xenopus 
Embryos 
Adult Xenopus laevis frogs were purchased from Nasco, Fort Atkinson, WI, USA and 
Xenopus Express, Vernassal, France. Xenopus males and females were kept separated 
from each other in 72-l, 170-l, and 200-l tanks filled with tap water and supplemented 
with common table salt and enrichments, according to the German animal welfare 
regulations. The water temperature was between 18°C and 20°C. The animals were 
held on 24-h day/night cycle with a 12-h day period. They were fed with food pellets 
(TabiMin, Tetra). The experimental procedures using Xenopus frogs were approved by 
the Regierung von Oberbayern, Munich, Germany (Permit 55.2-1-54-2531.6-3-10). 
3.1.1 In vitro fertilization 
In vitro fertilizations were performed to obtain Xenopus embryos that were developing 
synchronously. Xenopus females were primed with 350 to 1000 IU of hCG injected 
subcutaneous to induce ovulation. After incubation of 12 to 16 hours at 18°C, injected 
females were gently massaged to facilitate egg laying. Testes for in vitro fertilizations 
were dissected from the fatty body of sexual maturated Xenopus males, which had been 
subjected to lethal anesthesia using Tricaine mesylate (MS-222). Isolated testes were 
washed with PBS and transferred to testes medium for storage at 4°C. To initiate in vitro 
fertilization, freshly obtained eggs were covered with piece of testis macerated in 1 ml 1x 
MMR. After 5 min, 0.1x MMR was added and the fertilized eggs were incubated at 20°C. 
The jelly coats of cleavage stage embryos were dissolved by treatment with freshly 
prepared 2% cysteine solution. Dejellied embryos were extensively washed with 0.1x 
MMR.  
3.1.2 Culture of Embryos 
Groups of about 100 embryos were transferred with a plastic pipette to 5-cm Petri dishes 
and cultured in 0.1 x MMR at 20°C. The embryo cultures were checked regularly. Dead 
embryos and those with developmental abnormalities were removed. The medium was 
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changed daily. Embryos were staged according to at Nieuwkoop and Faber (Nieuwkoop 
and Faber, 1967). 
 
3.2 Assessment of Hair Cell Toxicity in Xenopus 
Embryos 
The assessment of hair cell toxicity was based on a standardized method established by 
S. M. Schmitt in the laboratory (S. Schmitt et al., manuscript in preparation). The in vivo 
test system permits the rapid and quantitative assessment of toxicity of waterborne 
drugs for hair cells of the lateral line system of Xenopus embryos. Five GBCAs were 
selected for testing: Omniscan, Magnograf, MultiHance, Dotarem, and Gadovist. 
Gentamicin and gadolinium served as positive controls. Each compound was assessed 
in at least three independent experiments using clutches from three different Xenopus 
females.  
3.2.1 Experimental setup 
48-well polystyrene microplates with 1.6 ml-volume well were used for embryo testing. 
Baskets to accommodate the embryos were homemade from 1.5 ml Eppendorf tubes as 
follows. The cap and the bottom of the Eppendorf tube were cut off using a sharp 
scalpel. Heat-stable nylon net (mesh) filters (100 µm pore size) was fused by heating at 
160°C to the bottom of the tube to creating a basket with perforated bottom (Fig. 12A). 
Each compound was tested at seven different concentrations. The test concentrations 
were as follows: 1 mM, 2 mM, 5 mM, 10 mM, 20 mM, 50 mM, and 100 mM. The dilutions 
were prepared in 1.5-ml Eppendorf tubes with 0.1 x MMR right before testing. Opened 
contrast agent bottles were sealed with Parafilm and stored under light protection at 
4°C. Gadolinium trichloride dilutions were prepared freshly every time. Gadolinium 
trichloride was tested at 0.5 µM, 1 µM, 2 µM, 5 µM, 10 µM, 20 µM, and 50 µM. 
Gentamicin dilutions were prepared from a 10 x stock solution (10 mg/ml), which was 
stored at 4°C. The following concentrations were tested: 0.1 µg/ml, 0.2 µg/ml, 0.5 µg/ml, 
1 µg/ml, 2 µg/ml, 5µg/ml, and 10 µg/ml. 
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The 48-well microplates were prepared by transferring 0.8 ml of each dilution and 
dispensing the dilution to the wells as shown in Fig. 11.  
Fig. 11. Schematic illustration of a 48-well 
microplate used for compound testing. Grey wells 
contain 0.8 ml of culture medium (0.1 x MMR). Wells 
shown with increasing degrees of red indicate wells 
filled with 0.8 ml of compound solution representing 
increasing compound concentrations. 
 
This described experimental setup was designed to enable efficient execution of the 
experimental procedures. For example, the setup with baskets harboring the embryos 
allows for easy, fast, and standardized treatments and the embryos in the baskets can 
be rapid moved to new wells for washing purposes (Fig. 12B).  
 
Fig. 12: Using basket to transfer embryos from one well to another. A: Side view of a 
custom-made basket with a Nylon mesh filter fused to the bottom. B: Transfer a basket with 
embryos from one well to a new one.  
3.2.2 Compound treatments 
Embryos at stage 41 (4 days post fertilization at 20°C) were selected for compound 
treatment. Appropriate compound dilutions were dispensed as outlined in Fig. 11. The 
homemade baskets were then placed into a 48-well microplate. Five stage 41 embryos 
were added into each baskets and incubated at 22°C for 24 hours. The most left well 
contained 0.1 x MMR and those embryos served as controls. Evaporation was 
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minimized by covering the microplates with a plastic lid and carrying out the incubations 
in a humidified incubator. 
3.2.3 Labeling and fixation 
After 24 hours of incubation, the embryos have reached stage 45. The baskets were 
transferred to wells filled with 0.1 x MMR for 5 min to stop the treatment and to wash the 
embryos. This step was repeated one more time to further reduce the exposure to the 
compound. 
For fluorescent labeling, a 2-mM stock solution was prepared by dissolving 100 µg FM1-
34FX in 89 µl DMSO and 22-µl aliquots were stored at -20°C in the dark. Under 
protection from light, an aliquot was dissolved in 0.1 x MMR to a final concentration of 2 
µM. 0.8 ml of labeling solution was dispensed to each well shortly before embryo 
staining was initiated. During and after labeling the embryos were kept protected from 
day light. After precisely 5 min of fluorescent labeling with FM1-34FX at room 
temperature, the baskets containing the embryos were transferred to fresh wells 
containing in 0.1 x MMR for 5 minutes of washing. The washing step was repeated one 
more time before the embryos were fixed with in freshly prepared MEMFA for 45 min on 
a horizontal shaker. For fixation, the embryos were transferred from baskets to wells 
containing MEMFA to provide them more space and to prevent fixation of bent or twisted 
embryos. Fixed embryos were transferred into PBS/EDTA and stored in the dark until 
they were used for imaging. The entire treatment procedure is summarized and 
illustrated in Fig. 13. 
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Fig. 13. Visualization of the treatment procedure to assess of the hair cell toxicity of 
GBCAs in Xenopus embryos. Baskets were supplemented with five stage-41 embryos each 
and transferred.to the 48-well dish. After the indicated incubation times, the embryos were 
transferred to the next row of wells either in the baskets or using a plastic pipette as shown.  
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3.2.4 Imaging of fluorescently labeled embryos 
The embryos were transferred to glass Petri dishes coated with PBS/EDTA-agarose and 
covered by PBS/EDTA. Small wells were scratched into the agarose to facilitate lateral 
positioning of the embryos for imaging. A Leica M205 FA fluorescence 
stereomicroscope was used to image the fluorescently labeled hair cells. Excitation and 
emission were detected with the Leica-GFP filter set (excitation filter: 470 nm/40 nm; 
Emission Filter: 525 nm/50 nm). From each embryo, a Z-stack consisting of 28 single 
pictures was generated. The Z-stack has covered an 810 µm of depth at a magnification 
of 24x and an exposure time of 192 ms. Each Z-stack was used to generate a single 
picture of each embryo using the Leica Application Suite (LAS) X software platform.  
3.2.5 Image processing and quantitation of fluorescence 
The image processing program Image J (Version 1.47; Wayne Rasband, NIH, USA) was 
used for the quantitative evaluation of the fluorescence intensity (FI). The picture files 
were opened using Image J, the RGB channels were split, and the channel “green” was 
selected. The analysis was restricted to the dorsolateral region of the lateral line system 
as shown in Fig. 14. This decision was based on the fact that (i) less natural variation 
between different embryos was observed for the dorsolateral lateral line system, and (ii) 
the dorsolateral part of the lateral line system is easier to image as it is located in flatter 
area of the embryo. The threshold for the fluorescence signals was set to 9000 until 
infinity. The area of interest was analyzed and data for size of stained area, mean value, 
minimum, maximum, and median fluorescence values were calculated.  
 
Fig. 14. Example of a Xenopus embryo at stage 45 after FM1-43FX labeling. The area of the 
lateral line system used for quantitation purposes is outlined in red. 
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3.2.6 Statistical evaluation 
The raw data obtained for each embryo was transferred to Microsoft Excel software 
(Microsoft Excel 2010 V14.0, Microsoft, USA). The mean value of fluorescence was 
multiplied by the size of the stained area to calculate the FI for each embryo as follows: 
FI = mean fluorescence x size of area 
The mean value and the standard deviation of the FI was calculated using all five 
embryos treated with the same compound concentration. If an embryo was not in the 
triple standard deviation confidence interval of the others (σ ≤ -3 or σ ≥ 3), it was 
assumed that the embryo was with a probability of 99.7% an outlier. Hence, it was 
excluded from the analysis. Only one outlier per compound concentration tested was 
tolerated. Otherwise, the entire 48-well dish was excluded and the experiment was 
repeated. 
Standardization of the FI values for each experimental set (i.e. 48-well dish) was 
necessary to permit a qualified statement about the impact of compounds on hair cell 
survival. The following formula was applied to the fluorescence intensity values: 
RFU [%] = FI[treated] / FI[untreated] x 100 
where, RFU indicates relative fluorescence unit; FI[treated] means the mean value of FI of 
all five embryos for a particular compound concentration tested; FI[untreated] refers to the 
mean value of FI of the five untreated control embryos.  
Setting the value of the untreated controls to 100% allowed (i) to bring the treated 
embryos for a given compound concentration into a standardized relation to the 
untreated control and (ii) to compare the results of all experiments between each other. 
To visualize the results, the calculated values were transferred to the statistics and 
graphing software SigmaPlot (SigmaPlot 12, Systat Software Inc., USA). The graph 
shown for each compound tested is composed from data obtained from three 
independent experiments. Mean values and standard deviations of the RFU were 
visualized using scatter and line graph with error bars.  
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The EC50 value is defined here as the effective concentration reducing the RFU to 50%. 
EC50 values were calculated with SigmaPlot by fitting a sigmoidal curve using a four-
parameter logistic curve algorithm. The statistical significance tests were performed 
through using ANOVA (Analyze of Variance) in SigmaPlot. The raw FI data for each 
embryo was compared to the others of the same experiment by One-Way-Analysis-of-
Variance. Significance level was defined as (p< 0.05). 
 
3.3 Assessment of Adverse Side Effects of GBCAs on 
Xenopus Embryogenesis 
The development of Xenopus embryos during contrast agent exposure was observed for 
five days to determine possible adverse side effects (ASE). The five contrast agents 
(Omniscan, Magnograf, MultiHance, Dotarem, and Gadovist) and gadolinium trichloride 
were assessed. Each compound was tested in three independent experiments using 
embryos from at least three different Xenopus females. 
3.3.1 Preparation of multiwell dishes 
The dilutions of the test compounds were prepared right before starting the treatments. 
The dilutions were made in 1.5-ml Eppendorf tubes using 0.1 x MMR. The embryos 
were treated with the dilutions in 48-well dishes. Each well contained 1 ml compound 
solution. Contrast agents and gadolinium trichloride were tested at seven different 
concentrations. GBCAs were tested at 1 mM, 2 mM, 5 mM, 10 mM, 20 mM, 50 mM, and 
100 mM (as in the hair cell toxicity assays above). Gadolinium trichloride was tested at 
final concentrations of 10 µM, 20 µM, 50 µM, 100 µM, 200 µM, 500 µM, and 1 mM. 
Control embryos were treated with 0.1 x MMR. 
3.3.2 Compound treatment 
Healthy normal embryos at stage 31 (2 days post fertilization at 20°C) were selected 
and washed in 0.1 x MMR. Five embryos were transferred to each well for compound 
testing. The multiwell dishes with the embryos were incubated at 22°C. To minimize 
evaporation, all wells that did not carry embryos were filled with 0.1 x MMR, the multiwell 
plates were covered with a lid, and they were transferred to an air humidified incubator. 
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The development of the embryos was checked twice a day when embryos reached the 
following embryonic stages: 33/34, 37/38, 39, 40, 41, 42, 43, 44, 45, 46, and 47. The 
experiments were terminated about 7 days post fertilization. The embryos were 
inspected to determine whether compound treatment caused developmental delays, 
externally visible abnormalities, or lethality. Any abnormal effects were documented. 
Dead embryos were removed from the well as soon as they were detected. 
3.3.3 Statistical evaluation 
Mean values and the standard deviations for pools of five embryos per well were 
calculated using Microsoft Excel software. These values were transferred to Sigmaplot 
and used to generate 3D Mesh plots, with embryonic stages, compound concentrations, 
and the observed abnormality (lethality) representing one of the three axes each. To 
simplify the illustrations, the mean values of the three surveys of every compound were 
used without plotting the standard deviation. Hence, no error bars are shown. LC50 is 
defined as the lethal concentration causing death of 50% of the treated embryos. Stage 
45 was chosen as the endpoint to calculate of the LC50 values. Line and scatter graph 
were generated with error bars. Sigmaplot calculated the LC50 value by fitting a 
sigmoidal curve to the stage 45 graphs using a four-parameter logistic curve algorithm. 
 
 
3.4 Materials 
 
Table 6. Test compounds 
Name Supplier Batch number (lot) 
Gadodiamide Gd-DTPA-BMA 
(Omniscan®) 0.5 M 
gadolinium(III) 5,8-bis(carboxylatomethyl)-2-
[2-(methylamino)-2-oxoethyl]-10-oxo-
2,5,8,11-tetraazado-decane-1-carboxylate 
hydrate 
GEHealthcare 11406948 
12447313 
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Gadopentetate-Dimeglumine Gd-DTPA 
(Magnograf®) 0.5 M 
gadolinium(III) 2-[bis[2-[carboxylatomethyl 
(carboxymethyl)amino]ethyl]amino]acetate  
Marotrast 93090J 
21125J 
Gadobenate-Dimeglumine Gd-BOPTA 
(MultiHance®) 0.5 M 
gadolinium(III) 2-[2-[carboxylatomethyl-[2-
[carboxylatomethyl(carboxymethyl)amino] 
ethyl]amino]ethyl-(carboxymethyl)amino]-3-
phenylmethoxypropanoate 
Bracco Imaging  S2P274C 
S4P253C 
Gadoterate-Meglumine Gd-DOTA 
(Dotarem®) 0.5 M 
gadolinium(III)2-[4,7,10-tris(carboxymethyl)-
1,4,7,10-tetrazacyclododec-1-yl]acetate 
Guerbet 13GD001B 
Gadobutrol Gd-DO3A-Butrol (Gadovist®) 
1 M 
gadolinium(III) 2,2′,2”-(10-((2R,3S)-1,3,4-
trihydroxybutan-2 yl)1,4,7,10 
tetraazacyclododecane-1,4,7-triyl)triacetate 
Bayer 24792A 
42805B 
Gentamicin 10 mg/ml Gibco 1142800 
Gadolinium 
Gadolinium(III)-chloride hexahydrate 
Sigma-Aldrich SLBG7250V 
SLBD9588V 
 
Table 7. Reagents 
Name Supplier  Batch number (lot) 
Aqua ad iniectabilia Braun  
Cysteine Solution: 2% L-Cysteine in H2O 
solution, pH 7.8 (adjusted with 10 x NaOH) 
  
Dimethyl sulfoxide (DMSO) Hybri-Max® Sigma-Aldrich D2650 
EDTA: 0.5 M EDTA, pH 8.0 (adjusted with 
NaOH) 
AppliChem A2937 
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EGTA: 0.5 M EGTA, pH 8.0 (adjusted with 
NaOH) 
AppliChem A0878 
Fetal calf serum Gibco 10110-153 
FM®1-43FX: 2 mM FM1-34FX in DMSO, 
stored at -20°C 
Invitrogen F35355 
Formaldehyde-solution 37% AppliChem A0877 
HEPES AppliChem A1069 
Human Chorionic Gonadotropin (hCG): 
2000 IU/ml hCG in H2O 
Sigma-Aldrich CG-10 
Hydrochloric acid 32% AppliChem A2078 
Magnesium sulfate heptahydrate Fluka 63140 
1 x Marc’s modified Ringer Solution 
(MMR): 100 mM NaCl, 2 mM KCl, 2 mM 
CaCl2, 1 mM MgSO4, 5 mM HEPES, pH 7.8 
  
0.1 x MMR: 1:10 dilution of 1 x MMR   
10 x MOPS/EGTA/Magnesium Sulfate 
(MEM salts): 1 M MOPS, 20 mM EGTA, 10 
mM MgSO4, pH 7.4, stored at 4°C, 
protected from light 
  
1 x MOPS/EGTA/Magnesium 
Sulfate/Formaldehyde Buffer (MEMFA): 
1:10 dilution of MEM salts, 3.7% 
Formaldehyde 
  
MOPS AppliChem A1076 
1 x Phosphate Buffered Saline/EDTA 
(PBS/EDTA): 1 M PBS, 10 mM EDTA, pH 
7.4 
  
PBS/EDTA-Agarose: 1 M PBS, 10 mM 
EDTA, 2% Agarose 
  
Phosphate Buffered Saline 10x pH 7.4 GIBCO 70011 
Potassium chloride AppliChem A2939 
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Sodium chloride AppliChem A4661 
Sodium Hydroxide 10N VWR 310933 
Testes Medium: 1 x MMR, 10% fetal calf 
serum, 2% gentamicin, sterilized by filtration 
(0.45 µm filter), stored at -20°C 
  
Tricaine mesylate Sigma-Aldrich A5040 
Ultra-Pure TM Agarose Invitrogen 16500 
 
Table 8. Tools and Instrumentation 
Name Supplier  Batch number (lot) 
COSTAR® 48 Well Plate Corning 3548 
Leica M205 FA Fluorescence 
Stereomicroscope 
Leica M205 FA 
Microtubes 1.5 ml EASY CAP SARSTEDT 72.690.550 
Plastic pipette   
NYLON NET FILTERS – 
100 µm NY1H 
Millipore NY1H02500 
Plastic Petri dishes Greiner bio-one 663102 
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4 RESULTS 
4.1  Assessing the Hair Cell Toxicity of GBCAs 
The hair cells of the Xenopus lateral line system served as a convenient in vivo test 
system to assess the toxic effects of GBCAs. Five GBCAs approved for use in humans 
were selected for testing: Gadodiamide (Omniscan®), Gadobutrol (Gadovist®), 
Gadobenate Dimeglumine (MultiHance®), Gadoterate Meglumine (Dotarem®), and 
Gadopentetate Dimeglumine (Magnograf®). Compounds with known hair cell toxicities, 
such as gadolinium and the aminoglycoside antibiotic gentamicin, served as positive 
controls. Embryos simply incubated in the culture medium (0.1 x MMR) were used as 
negative controls. Xenopus embryos were treated in 48-well microplates with GBCA 
concentrations ranging from 1 mM to 100 mM for 24 hours at 22°C. Subsequently, the 
hair cells were labeled with the fluorescent dye FM1-43FX and fixed in MEMFA. Loss of 
fluorescent labeling correlates with compound-induced damage to hair cells. Hence, the 
fluorescence intensity (FI) was quantified after microscopic imaging. Every compound 
was tested with five embryos per well at each concentration in at least three 
independent experiments. 
 
4.2 Free Gadolinium Shows Considerable Hair Cell 
Toxicity  
Gadolinium trichloride hexahydrate, a colorless, hygroscopic, water-soluble compound, 
was used as a source for free gadolinium. Gadolinium treatment of Xenopus embryos 
resulted in a concentration-dependent decrease of fluorescent staining of hair cells, 
indicating toxicity of the compound (Fig. 15). At a gadolinium concentration of 5 µM, the 
lateral line system appeared to be widely damaged, and the treatment with 50 µM 
almost completely destroyed the lateral line. There were no other morphological 
abnormalities identifiable in the treated embryos. Fig. 16 shows the quantitative analysis 
of the fluorescence associated with the hair cells of the dorsolateral aspects of the 
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lateral line system. The obtained dose-response curve demonstrated that RFU declined 
to nearly zero at gadolinium concentrations of 50 µM and higher with an estimated EC50 
value of 9.7 µM.  
 
Fig. 15. Treatment of Xenopus embryos with gadolinium trichloride. The embryos were 
treated for 24 hours with the compound and subsequently labeled with FM1-43FX. Brightfield 
images are shown on the left with corresponding fluorescent ones on the right. A: Control 
untreated embryo; B, C: Representative embryos treated with 5 µM (B) and 50 µM (C) 
gadolinium trichloride. 
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Fig. 16. Dose-response curve relating the gadolinium trichloride concentration to the 
fluorescent staining of lateral line hair cells. Fluorescent staining was performed after 24 
hours of gadolinium treatment. Mean values and standard deviations (error bars) are shown 
(n=3). Statistical evaluation and significance calculations were done using SigmaPlot. Nonlinear 
regression with a four-parameter logistic curve (blue) was used to calculate of indicated EC50 
value.  
 
4.3 Gentamicin and Gadolinium have Comparable Hair 
Cell Toxicities  
The aminoglycoside gentamicin is known for its toxicity towards hair cells of the lateral 
line system. We therefore asked how its toxicity compares to that of gadolinium. As 
shown in Fig. 17, gentamicin treatment reduced fluorescent staining of hair cells in a 
concentration-dependent manner towards zero. The calculated EC50 value was 0.96 
µg/ml, which is approximately 2.01 µM. In summary, both gadolinium and gentamicin 
induce hair cell toxicity at concentrations in the low µM range.  
. 
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Fig. 17. Dose-response curve relating the gentamicin concentration to the fluorescent 
staining of lateral line hair cells. Fluorescent staining was performed after 24 hours of 
gentamicin treatment. Mean values and standard deviations (error bars) are shown (n=3). 
Statistical evaluation and significance calculations were done using SigmaPlot. Nonlinear 
regression with a four-parameter logistic curve (blue) was used to calculate the indicated EC50 
value. 
 
4.4 Differential Effects of GBCAs on Hair Cells of 
Xenopus Embryos 
The assessment of the toxicity of GBCAs for the hair cells of the lateral line system of 
Xenopus embryos resulted in no or only very moderate loss of RFU over the 
concentrations tested (Fehler! Verweisquelle konnte nicht gefunden werden.). I
mportantly, these concentrations were 2000-fold higher than those used to test 
gadolinium (100 mM vs 50 µM). Overall, the mean RFU values obtained for the different 
GBCAs after embryo treatment never declined below half of control RFU. Nevertheless, 
interesting differences between the toxicities of the GBCAs were noticeable. While 
Omniscan and Gadovist displayed little to no toxicities for Xenopus lateral line hair cells, 
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moderate but statically significant loss of fluorescent staining was observed after 
treatment with Dotarem and Magnograf. Unexpectedly, the latter and MultiHance were 
found to be lethal for the embryos at 100 mM, the highest concentration tested over the 
24-hour incubation period in three independent experiments.  
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Fig. 18. Dose-response curves relating GBCA concentrations to the fluorescent staining 
of Xenopus lateral line hair cells. Fluorescent staining was performed after 24 hours of GBCA 
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treatment. Mean values and standard deviations (error bars) are shown. Asterisks indicate 
significance with p>0.05. At 100 mM, Magnograf and Multihance cause embryonic lethality 
within 24 hours. Statistical evaluation and significance calculations were done using SigmaPlot. 
All tested compounds passed normality and equal valiance test.  
 
4.5 Assessing the Effects of GBCA Treatment on 
Xenopus Embryogenesis 
As mentioned above, treatment of Xenopus embryos with Magnograf or MultiHance at a 
final concentration of 100 mM was lethal for the embryos within 24 hours of incubation. 
These findings raised the question whether prolonged treatment with GBCAs had any 
adverse effects on Xenopus embryogenesis. Furthermore, the concentrations causing 
lethality in 50% of the embryos (LC50) were to be established, where appropriate. 
Gadolinium and the five GBCAs were used to monitor their effects on Xenopus 
embryogenesis between stage 31 to 47, covering a period of five days at 20 °C. Dose-
response studies were performed in 48-well dishes with five embryos per well. Control 
wells contained embryos in 0.1 x MMR only. The embryos were inspected every 12 
hours using a stereomicroscope for any externally discernible malformations or 
phenotypes. Each compound was tested in three independent experiments with 
comparable results. 
 
4.6 Gadolinium Treatment Causes Embryonic Lethality 
Gadolinium trichloride treatments were performed with concentrations ranging from 10 to 
1000 µM. Embryonic lethality was observed at 20 µM and higher concentrations. At 100 
µM, the embryos reached stage 41 before they started to die, whereas embryos died 
immediately after exposure to a concentration of 1000 µM. Using stage 45 as an 
endpoint, a LC50 value of 56.7 µM was estimated (Fig. 19). 
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Fig. 19. Lethality of Xenopus embryos occurring during gadolinium trichloride treatment. 
A: 3D-Mesh-Plot of embryonic lethality, stage, and concentration (n=3) B: Line and scatter plot 
of lethality at stage 45. 
 
4.7 Differential Effects of GBCA Treatments on 
Xenopus Embryogenesis 
Xenopus embryos were treated with GBCAs at concentrations ranging from 1 mM to 100 
mM. Treated embryos were not only scored for lethality, but also inspected for 
hemorrhages, edema, and other visible abnormalities. Significant differences were 
observed between the GBCAs studied here. Omniscan treatment even at the highest 
concentration of 100 mM had no obvious effects on Xenopus embryogenesis as shown 
in Fig. 20.  
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Fig. 20. Wild-type phenotype observed with Xenopus embryos at stage 45 after 72 hours 
of treatment with 100 mM Omniscan. A: Control embryo. B: Embryo treated with 100 mM 
Omniscan.  
 
By contrast, treatment of Xenopus embryos with 100 mM Magnograf caused lethality 
after 24 hours (Fehler! Verweisquelle konnte nicht gefunden werden.). Before dying, t
he embryos often displayed developmental delays and reduced swimming activity (not 
shown). 
 
Fig. 21. Appearance of a dead Xenopus embryo observed 24 hours after treatment with 
100 mM Magnograf. 
 
Besides Omniscan, Gadovist treatment had also no detectable effects on Xenopus 
embryogenesis as documented in Fig. 22 and Fig. 23, respectively.  
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Fig. 22. Absence of lethality in Xenopus embryos treated with Omniscan. A: 3D-Mesh-Plot 
of embryonic lethality, stage, and concentration (n=3) B: Line and scatter plot of observed 
lethality at stage 45. 
 
 
 
Fig. 23. Absence of lethality in Xenopus embryos treated with Gadovist. A: 3D-Mesh-Plot 
of embryonic lethality, stage, and concentration (n=3) B: Line and scatter plot of observed 
embryonic lethality at stage 45. 
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Treatment of embryos with Magnograf, MultiHance, and Dotarem led to dose- and 
incubation time-dependent lethality as documented in Fig. 24 to 26. All embryos treated 
with 100 mM Magnograf or MultiHance died within 24 hours, by when they had reached 
stage 37/38 (Fig. 24 and Fig. 25). At 50 mM, MultiHance was more lethal than 
Magnograf. The estimated LC50 values for Magnograf and MultiHance were 95.5 mM 
and 49.7 mM, respectively. 
 
 
Fig. 24. Lethality of Xenopus embryos caused by Magnograf treatment. A: 3D-Mesh-Plot of 
embryonic lethality, stage, and concentration (n=3) B: Line and scatter plot of lethality at stage 
45 for LC50 calculation. Standard deviation was 0. 
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Fig. 25. Lethality of Xenopus embryos caused by MultiHance treatment. A: 3D-Mesh-Plot of 
embryonic lethality, stage, and concentration B: Line and scatter plot of lethality at stage 45 for 
LC50 calculation. Error bars indicate standard deviation. 
Finally, embryos treated with Dotarem also showed dose- and incubation time- 
dependent lethality. However, lethality occurred later and approximately half of the 
embryos treated with 100 mM of Dotarem survived until the end of the experiment. The 
LC50 value were estimated to be about 107 mM (Fig. 26). A summary of the estimated 
EC50 values for hair cells toxicity and the LC50 values are shown in Table 9.  
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Fig. 26. Lethality of Xenopus embryos caused by Dotarem treatment. A: 3D-Mesh-Plot of 
embryonic lethality, stage, and concentration (n=3) B: Line and scatter plot of lethality at stage 
45 for LC50 calculation. Error bars indicate standard deviation. 
 
Table 9. Compilation of the estimated EC50 and LC50 values for lateral line hair cell toxicity 
and lethality, respectively, after compound treatment 
Compound Ionicity Structure EC50 LC50 
Gentamicin n.a. n.a. 2.0 µM n.d. 
Gadolinium trichloride n.a. n.a. 9.7 µM 56.7 µM 
Omniscan Non-ionic Linear a b 
Magnograf Ionic Linear a 95.5 mM 
MultiHance Ionic Linear a 49.7 mM 
Dotarem Ionic Macrocyclic a 107 mM 
Gadovist Non-ionic Macrocyclic a b 
Abbreviations: a, hair cell toxicity too low for the calculation of EC50 values; b, no embryonic 
lethality was observed; n.a., not applicable; n.d., not determined.  
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5 DISCUSSION 
GBCAs are routinely used for MRI, where they are typically applied intravenously and 
excretion occurs via the kidney. In recent years, intratympanic GBCA injection followed 
by enhanced inner ear MRI has become a key diagnostic procedure in the diagnosis of 
Meniere´s disease. Gadolinium (Gd3+), the main constituent of GBCAs, is highly toxic in 
its free form because of its similarities to Ca2+, which is an important electrolyte required 
for heart and skeletal muscle contraction and nerve transmission. To harness the 
paramagnetic properties of Gd3+ for MRI purposes, the cation has to be chelated with 
polyaminopolycarboxylic acid that serves as ligand. Unstable chelates are considered 
unsafe for human use, as they could release free Gd3+. A better understanding of the 
biodistribution and safety of GBCAs is therefore of high priority in order to address the 
serious safety concerns of these agents. In the present study, the lateral line system of 
Xenopus embryos was used as a fast, reproducible, and cost-effective in vivo test 
system to assess the hair cell toxicity potential of five commonly used GBCA that 
represent the main classes of GBCAs. The compounds were tested as concentrations 
similar to those used in humans. In addition, the concentrations lethal for Xenopus 
embryogenesis were established. Overall, the present work represents the first 
comparative in vivo toxicity assessment of multiple GBCAs in a vertebrate animal model.  
 
5.1 Xenopus embryos are a Valid and Reliable 
Vertebrate Model Organism for Hair Cell Toxicity 
Testing 
The lateral line of Xenopus embryos and tadpoles represents an ectodermal sensory 
organ consisting of mechanosensitive hair cells that detect water movements. Given its 
location in the skin, its hair cells are accessible to any drug or agent that presented in 
the media. This is a significant advantage over mammalian test systems that require oral 
or intravenous administration of compounds to assess their ototoxicity potential. After 
induction of ovulation, a single Xenopus female will give rise to hundreds of embryos, 
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which can be employed for extensive and comprehensive compound testing studies. 
Agents can be assessed in vivo over a wide concentration range to document hair cell 
toxicity. The hair cells of the lateral line can be selectively stained in batch with the 
fluorescent dye FM1-34FX. The dye is fixable and staining is confined to the lateral line’s 
hair cells, if administered in the media to intact embryos (S. Schmitt et al., manuscript in 
preparation). Compound-induced damage to lateral line hair cells will manifest in 
reduced fluorescent staining, which can be assessed by fluorescence stereomicroscopy. 
Quantitation of the remaining fluorescence after compound treatment serves as a basis 
to establish dose-response relationships and calculate of EC50 values. In addition, the 
treatment of the whole organism allows for the detection of compound-induced side 
effects and/or lethality. In the present study, each compound was assessed with at least 
120 embryos for hair cell toxicity and typically a further 120 were used to characterize 
any possible adverse effects. Using a 48-well microplate set-up, the compound testing 
experiments could be performed efficiently and in a standard manner by harboring the 
embryos in home-made baskets. Embryos were moved from well to well to carry out the 
treatment, washing and staining steps with minimal transfer of medium.  
By limiting the analysis of the fluorescent staining of the hair cells to the dorsolateral 
portions of the lateral line, natural variations from embryo to embryo could be addressed 
and imaging of the fluorescent hair cells was facilitated. Typically, control and treated 
embryos for each experimental set were derived from the same mating. Finally, the 
aminoglycoside gentamicin, a well-known ototoxic drug, was used to determine the 
effective concentration reducing fluorescent staining by half (EC50). The obtained EC50 
of 2.01 µM for gentamicin was very similar to the previously determined EC50 of 1.01 µM 
in our laboratory (S. Schmitt et al., manuscript in preparation). This demonstrates that 
the Xenopus-based hair cell toxicity test system is robust and reproducible in the hands 
of different investigators.  
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5.2. Closer Evolutionary Relationship Between 
Humans and Xenopus than Zebrafish 
The lateral line of zebrafish larvae has been prominently used for large-scale in vivo hair 
cell toxicity screening purposes (Chiu et al., 2008). However, the toxicity of GBCAs has 
not been assessed in zebrafish to date. The zebrafish and Xenopus model systems 
share many experimental advantages, such the small sizes of the embryos, access to 
hundreds of embryos, and the presence of a lateral line system. With Xenopus ovulation 
and egg laying can be initiated at any time by hCG injection. Furthermore, frogs share 
an evolutionary history with mammals that is 90–100 million years longer than fish. It is 
therefore not surprising that the degree of morphological and functional similarities to 
humans is higher with Xenopus than zebrafish (Wheeler and Brandli, 2009). 
 
5.3 Large Scale Dose-Response Experiments are 
Feasible with Xenopus Embryos  
Guinea pigs and rats represent standard animal models for ototoxicity testing (Lataye et 
al., 2003; Poirrier et al., 2010). Testing is however restricted to the hair cells of the inner 
ear as mammals lack lateral line organs. Testing of water-borne compounds using hair 
cells of the lateral line offers the advantage that the compounds can administered and 
exposed at clearly defined concentrations with minimal interference by ADME 
(absorption, distribution, metabolism, and excretion) in mammalian in vivo models. 
Besides simple drug administration, moderate compound quantity requirements, low 
animal husbandry costs, and a simplified regulatory procedure are further advantages in 
favor of using Xenopus embryos for hair cell toxicity testing in comparison to rodents. 
However, rodents are evolutionary closer to humans and Xenopus lateral line hair cells 
may differ from inner ear hair cells in their sensitivity to toxic insults. Furthermore, 
Xenopus hair cell toxicity experiments are performed with embryos, thus the observed 
effects could have been influenced by developmental plasticity. The most compelling 
advantage of employing Xenopus embryos for drug toxicity testing is the possibility to 
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perform experiments that require large animal numbers, such as dose-response or 
comparative studies, as demonstrated in the present work.  
 
5.4. Xenopus as a Useful Test System to Estimate the 
Risks of GBCA Enhanced Inner Ear MRI 
The key advantage of GBCA enhanced inner ear MRI, as it is used for the visualization 
of ELH in Meniere´s and other diseases, is its ability to discriminate peri- and 
endolymphatic spaces by a selective GBCA enhancement in the perilymph, but not in 
the endolymph. The uptake of intratympanically administered GBCAs in the perilymph is 
very limited. After an intratympanic application of eight-fold diluted GBCA, the 
concentration in the perilymph is only 0.1 mM, which represents a 5000-fold dilution 
(Pyykko et al., 2010). High resolution images of strong field (9.4 T) MRI in mice could 
not detect a GBCA-increased signal intensity in the endolymph, when applied 
intravenously (Counter et al., 2013). In the present work, we studied GBCAs at 
concentrations from 1 to 100 mM. Hence, GBCAs toxicity testing in Xenopus was done 
at concentrations at and above the clinically applied concentration in patients, as well as 
the estimated concentration in the endolymph. Rupture of the Reissner´s membrane or 
morphological variations could lead to a considerable increase of GBCA concentrations 
in the endolymph. These special situations are adequately represented by the 
concentration ranges used in the present study. GBCA exposure time was 24 hours for 
Xenopus embryos. When performing inner ear MRI, the GBCA elimination half-life from 
perilymph was 6.6 hours for intratympanic and 3.2 hours for intravenous administration 
in guinea pigs (Li et al., 2013). This suggests that the treatment period used with 
Xenopus embryos was sufficiently similar. Previous studies have suggested, that the 
ototoxicity of intratympanically injected GBCAs could be caused by effects in other 
targets than hair cells (Kakigi et al., 2008; Nonoyama et al., 2016). It is likely that these 
aspects of GBCA toxicity cannot be captured in the Xenopus lateral line assay. 
Nevertheless, the assessment of GBCA toxicity for hair cells, which represents the key 
sensory organs of the inner ear, remains of primary concern.  
DISCUSSION                      74 
5.5. Assessment of GBCA-induced Hair Cell Toxicity in 
Xenopus 
Five common extracellular fluid GBCAs, approved for human application by the EMA 
and the FDA, were assessed for hair cell toxicity using the Xenopus lateral line. The 
selected GBCAs differ in the molecular structure of their chelates and the associated 
ionic properties. The examples cover all four GBCA types based on ligand structure 
(linear and macrocyclic) and ionicity (ionic or non-ionic). In general, the stability of the 
chelation of gadolinium to the ligand determines the safety of GBCAs. Non-ionic linear 
chelates are considered the least stable, while the ionic macrocyclic chelates are the 
most stable (Dekkers et al., 2018; Sherry et al., 2009). The toxicity of free gadolinium 
and the aminoglycoside gentamicin for hair cells of the mammalian inner ear is well 
established. In the present study, we demonstrate these two ototoxic compounds also 
damage hair cells of the lateral line of Xenopus embryos. With EC50 values of 2.0 µM 
and 9.7 µM for gentamicin and gadolinium trichloride, respectively, both compounds 
were toxic in the low µM range. These findings provide further validation for the use of 
the Xenopus lateral line system to assess ototoxicity. Unlike free gadolinium, none of the 
GBCAs induced considerable lateral line hair cell toxicity and hence no EC50 values 
could be established for the five GBCAs tested. Notably, the highest test concentration 
of 100 mM was 10’000-fold above the EC50 value of 9.7 µM for gadolinium-induced hair 
cell toxicity. While GBCA toxicity to hair cells of the lateral line was very limited, 
Magnograf and Dotarem causes a reduction in fluorescent dye labeling that was 
statistically significant. While both of these GBCA belong to the ionic class, which is 
associated with higher osmolality and toxic active ions, they differ in the structure of the 
ligand. Magnograf consists of a linear ligand, whereas Dotarem has a macrocyclic one. 
MultiHance, the third GBCA of the ionic class tested here, also showed reduction of 
fluorescent hair cells staining, which was however not statistically significant. Of all the 
GBCAs tested, Omniscan (based on a non-ionic linear chelator) and Gadovist (non-ionic 
macrocyclic) appear to be the least toxic for Xenopus lateral line hair cells. 
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5.6 GBCA-induced Hair Cell Toxicities Correlate across 
Animal Species 
How do the findings on GBCA hair cell toxicities in Xenopus embryos compare to 
studies using other animal models? To date, no other animal model study than the 
present one has systematically investigated the hair cell toxicities of five different 
GBCAs in a comparative and standardized manner. Furthermore, cross-species 
comparison of GBCA toxicities has been difficult partly due to differing test 
methodologies. For Magnograf, studies in guinea pigs and human patients suggest that 
intratympanic application of an eight-fold dilution (62.5 mM) of the agent was non-toxic 
(Louza et al., 2015; Suzuki et al., 2011). However, the estimated GBCA concentration in 
the perilymph after intratympanic administration is only about 0.1 mM (Pyykko et al., 
2010), and furthermore there is no evidence for permeation of the agent into endolymph 
and access to hair cells (Counter et al., 2013). Under the test conditions with Xenopus 
embryos, the hair cells of the lateral line are exposed directly to the GBCAs. The finding 
that Magnograf treatment causes moderate loss of fluorescent staining of lateral line hair 
cells at 10 mM and above may indicate that there is an inherent ototoxicity of 
Magnograf, which is only becomes apparent when hair cells are exposed directly to the 
agent.  
The most widely studied GBCA regarding hair cell toxicity is Omniscan. In present study, 
no evidence for hair cell toxicity of Omniscan was observed for Xenopus lateral line hair 
cells, even at the highest concentration of 100 mM studied. In guinea pigs, Omniscan 
treatment similarly failed to not evoke physiological or morphological damage to hair 
cells at concentrations up to 500 mM (Duan et al., 2004; Suzuki et al., 2011; Zou et al., 
2009). By contrast, Omniscan treatment of isolated bullfrog inner ear hair cells using  
four- to 16-fold dilutions of the agent (125 mM to 31.25 mM) caused significant toxicity 
(Tanaka et al., 2010). In mice, intratympanic administration of Omniscan caused mild 
ototoxicity as demonstrated by a significant change in auditory brainstem response 
(Nonoyama et al., 2016). Interestingly, the authors suggest that Omniscan may cause 
ototoxicity by a mechanism that does not involve outer hair cells, since these were found 
to be morphologically intact. Using in guinea pigs, Kakigi et al. (2008) reported toxic 
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effects to the stria vascularis and the endocochlear potential after intratympanic 
administration of Omniscan at concentrations over 32 mM (Kakigi et al., 2008). 
Importantly, no incidences of ototoxicity have been reported to date after intratympanic 
administration of eight-fold diluted Omniscan in humans (Louza et al., 2013). The 
absence of lateral line hair cell toxicity after treatment of Xenopus embryos with 
Omniscan is therefore consistent with the apparent lack of ototoxicity after intratympanic 
application of Omniscan in human patients.  
 
5.6. Toxicity of GBCAs for Xenopus Embryos can be 
Attributed to Ionicity 
While performing hair cell toxicity testing, we observed that the treatment with 
Magnograf or MultiHance at 100 mM (but not 50 mM) was lethal for the embryos within 
24 hours. Interestingly, both agents are examples of GBCAs based on ionic linear 
chelates. To assess adverse side effects and systemic toxicity of GBCAs in greater 
detail, Xenopus embryos were treated with the agents at concentrations ranging from 1 
mM to 100 mM and the embryos were observed over a treatment period of five days for 
evidence of GBCA-induced lethality. Free gadolinium, which was toxic with an LC50 of 
56.7 µM, was used as a benchmark. None of the GBCAs tested were toxic at 
concentrations up to 20 mM. Beyond this concentration, significant differences in 
lethality were observed between the different GBCAs tested. While Omniscan and 
Gadovist caused no lethality even at 100 mM, Magnograf, MultiHance, and Dotarem 
treatment led to a dose- and incubation time-dependent increase of embryonic lethality 
with estimated LC50 values ranging from 49.7 to 107 mM. The nonlethal Omniscan and 
Gadovist represent non-ionic GBCAs with linear and macrocyclic ligand structures, 
respectively. By contrast, ionic GBCAs caused lethality at concentrations of 50 mM or 
higher irrespective of the ligand structure. It therefore appears that ionicity (and not 
ligand structure) represents the key physicochemical determinant for the lethality of 
GBCAs in Xenopus embryos. Ionic GBCAs harbor counterions bound via ionic bonds to 
the ligand that dissociate in water and increase the osmolality. The presence of 
counterions can therefore contribute to the toxicity of GBCAs (Kun and Jakubowski, 
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2012). The skin of aquatic fish and amphibian larvae is primarily permeable to small, 
hydrophobic organic molecules with logP values higher than +1 (Wheeler and Brandli, 
2009). As summarized in in Table 3, all GBCAs tested in the present study have logP 
values ranging between -3.16 and -2.0. Given their hydrophilicity, it is unlikely that 
GBCAs are absorbed by Xenopus embryos. In addition, the ionic GBCAs had higher 
molecular masses (754-1058 g/mol) than the non-toxic, non-ionic GBCAs (592-605 
g/mol), which correlates negatively with compound absorption. Finally, active ingestion 
of GBCAs by Xenopus embryos can be excluded as food uptake starts after stage 45, 
the endpoint used to determine compound-induced lethality. It is therefore most likely 
that the lethal effects of ionic GBCAs on Xenopus embryogenesis can be attributed to 
the increase in osmolality in the culture media, which is caused by the massive release 
of counterions at high GBCA concentrations. 
 
5.7 Comparison of GBCA Toxicities across Animal 
Species 
The toxicity and lethal doses of GBCAs for mammals have been established primarily for 
rats in various studies (see Table 10 for references). A direct comparison of the 
quantitative data for a given GBCA between Xenopus and mammalian test systems is 
however difficult due differences in administration mode, testing situation (in vivo vs. in 
vitro) and age of the individuals used for testing. We therefore compared the rank orders 
of reported toxicities (Table 10). Interestingly, the low toxicity of the non-ionic GBCAs 
Omniscan and Gadovist correlated well with results obtained from studies in rats and 
human blood. For example, lethality testing of GBCAs in rats by intravenous 
administration of GBCAs in rat demonstrated that Omniscan and Gadovist were 
significantly less toxic than the other GBCAs. As for Xenopus embryos, acute lethality of 
GBCAs in rats correlates well with the iconicity, where ionic GBCAs exhibit higher 
toxicity than non-ionic ones irrespective of the ligand structure. Chelate stability, i.e. 
release of gadolinium, appears therefore to be less of factor for acute lethality than ionic 
imbalances cause by counterion release by ionic GBCAs. A different perspective is 
provided by the risk ranking of GBCAs for nephrogenic systemic fibrosis (NSF) (EMA, 
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2010). The fibrosis risk is determined in part by gadolinium release from the chelate and 
the tissue retention of GBCAs. Macrocyclic GBCAs are considered to have a lower 
fibrosis risk than linear ones. Hence, Dotarem scores low, while Omniscan’s risk is high 
(Table 10).  
Table 10: Comparison of GBCA toxicity rank orders across animal models  
Toxicity high                                                                                  low 
Xenopus embryos 
External 
administration 
(LC50, mM) 
MultiHance (49.7) Magnograf (95.5) Dotarem (107) Omniscan (ND) 
                                                                                   Gadovist (ND) 
Rat  
i.v. administration 
(LD50, mmol/kg)  
(Oksendal and Hals, 
1993), (Gries, 2002) 
Magnograf (8)       MultiHance (10)   Dotarem (18)   Omniscan (25) 
                                                                                   Gadovist (25) 
Human blood  
In vitro  
(Gd-release in %) 
(Frenzel et al., 2008) 
Omniscan (20)                Magnograf (1.9)                Dotarem (< 0.1)
                    MultiHance (1.9)         Gadovist (< 0.1) 
Rat  
i.v. administration 
(Gd-release in µM 
Gd/g skin) 
(Sieber et al., 2008) 
Omniscan (~ 1.7)            Magnograf (~ 0.2)          Dotarem (~ 0.05)
                    MultiHance (~ 0.1)       Gadovist (~ 0.05) 
Risk for 
nephrogenic 
systemic fibrosis 
(EMA, 2010) 
Omniscan (high)              MultiHance (medium)         Dotarem (low)  
Magnograf (high)                                                        Gadovist (low) 
Examples of toxicity rank orders as determined in the present study and the cited references.  
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6 CONCLUSIONS AND PERSPECTIVES 
The issues concerning the toxicity of GBCAs have been gaining extensive attention in 
recent years. In 2007, the development of nephrogenic systemic fibrosis in patients with 
severe renal insufficiency was linked to exposure of high doses of gadolinium (Daftari 
Besheli et al., 2014; Perazella, 2009). More recently, gadolinium deposition after i.v. 
administration in healthy individuals was confirmed challenging the safety of GBCAs 
(Kanda et al., 2015; Kanda et al., 2017; McDonald et al., 2017; Ramalho et al., 2016). 
Finally, in 2017 the EMA recommended to suspend the use of four GBCAs of the linear 
ligand class, mainly due to the higher risk of retention and accumulation in the human 
body (Dekkers et al., 2018). Importantly, the suspended linear GBCAs are of both the 
ionic and non-ionic type. The use of a further linear GBCA, MultiHance, was restricted, 
whereas maintenance was only recommended for Primovist as the only linear GBCA 
left. In the present study, the hair cell toxicities and potentially lethal effects of five 
GBCAs were examined using Xenopus embryos. Among the tested GBCAs in Xenopus, 
Magnograf and Omniscan are now recommended for suspension and Multihance is 
under restriction by the EMA. Only the macrocyclic Dotarem and Gadovist are 
considered GBCA safe for use in humans.  
How well does toxicity testing of GBCAs in Xenopus embryos predict their effects in 
human patients? Regarding potential ototoxicity, the lateral line hair cell toxicity tests in 
Xenopus embryos failed to reveal overt toxicity of any of the tested agents. While mild 
and statistically significant hair cell damage was detected with two ionic GBCAs 
(Magnograf, Dotarem), in no case was it possible to calculate EC50 values. For all 
assessed GBCAs, hair cell toxicity was evidently absent or low at concentrations used 
clinically for intratympanic administrations. Overall, hair cell toxicity testing in Xenopus 
provides further supportive evidence for the safe use of GBCAs in MR imaging to study 
inner ear defects, such the visualization of EH. The importance of stable binding of 
gadolinium to its ligand was underscored by the potent toxicity of free gadolinium (EC50: 
9.7 µM) towards the hair cells of the lateral line. Concerns for general toxicity of GBCAs 
arose from the observation that 24-hour incubation of Xenopus embryos with 100 mM of 
Magnograf or MultiHance resulted in embryonic lethality. Long-term treatment of 
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Xenopus embryos with water-borne GBCAs revealed that all GBCAs of the ionic type 
irrespective of the ligand structure caused embryonic lethality at concentrations above 
50 mM. By contrast, none of the non-ionic GBCAs tested were lethal for Xenopus 
embryos. The general toxicities of GBCAs observed in Xenopus embryos were in line 
with previous observation from testing in rats. It should be noted that the Xenopus 
toxicity tests do not predict the long-term effects of GBCAs in the vertebrate body, such 
as damages caused by gadolinium retention in the brain and other organs. In fact, it is 
very likely that there is no uptake of GBCAs at all into Xenopus embryos as the animals 
do not feed yet and the agents are too hydrophilic to be absorbed via the epidermis.  
Overall, the present work establishes Xenopus embryos as a valid, reliable, and 
objective test system to assess and quantitate the hair cell toxicity of any water-borne 
GBCA. Given the virtually unlimited access to Xenopus embryos, large-scale testing of 
GBCAs for comparative purposes is now feasible. In our opinion, Xenopus hair cell 
toxicity testing may in future replace expensive and laborious testing in mammals as 
initial, in vivo whole organism test system for novel experimental GBCAs. In this context, 
only those GBCAs scoring as non-toxic in Xenopus embryos would be advanced for 
testing in mammalian animal models. The recently updated recommendations of the 
EMA for the use of GBCAs in humans (Dekkers et al. 2018) include five agents that 
were not yet assessed in Xenopus embryos. These include Primovist (gadoxenate), the 
only linear GBCA left on the recommendation list, and the linear Optimark 
(gadoversetamide) and macrocyclic Prohance (gadoteridol) that could be assessed in 
Xenopus for hair cell toxicities.  
The most practical conclusions that can be drawn from the Xenopus GBCA toxicity 
studies reported here and the recent recommendation by the EMA on the use of GBCAs 
(Dekkers et al. 2018) are as follows. First, Gadovist and Omniscan have emerged as 
those GBCAs causing the least damage to Xenopus lateral line hair cells. Second, 
Gadovist and Omniscan, both representing GBCAs of the non-ionic type, appear to have 
favorable safety profiles given that they do not cause any lethality in Xenopus embryos. 
Finally, the recent safety recommendation by the EMA suspends the use of Omniscan. 
Taken together, this favors the use of the non-ionic macrocyclic Gadovist for 
intratympanic enhanced MRI.  
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8   APPENDICES 
8.1  Abbreviations 
% percent 
~ (tilde) approximately 
< smaller than 
> bigger than 
°C degree Celsius 
3D three-dimensional 
3D-FLAIR three-dimensional fluid attenuated inversion recovery 
3D-IR TSE three-dimensional inversion-recovery turbo spin echo 
µg microgram 
µl microliter 
µM micromolar 
µm micrometer 
µmol micromol 
ABR auditory brainstem response 
ANOVA analysis of variance 
CaCl2 calcium chloride 
cm centimeter 
Cl- chloride ion 
dB decibel (a logarithmic unit of measurement in acoustics) 
DMSO dimethylsulfoxide 
DNA deoxyribonucleic acid 
e.g. for example (Latin “exempli gratia”) 
EC50 effective concentration at 50% 
ELH endolymphatic hydrops 
EMA European Medicines Agency 
FDA Food and Drug Administration (US) 
F fluorescent intensity 
FITC Fluorescein isothiocyanate 
FM1-43FX 
n-(3-aminopropyldiethylammoniumpropyl)-4-(dibutylamino)-
styryl 
g gram 
ga gauge 
GBCA gadolinium-based contrast agent 
Gd3+ gadolinium ion 
h hour 
H+ proton 
HCl hydrochloric acid 
HCO3− hydrogencarbonate 
H2O water 
hCG human chorionic gonadotropin 
HEPES 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid 
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hpf hours post fertilization 
H2SO4 sulfuric acid 
i.t. intratympanic 
i.v. intravenous 
IU international units 
K+ potassium ion 
KCl potassium chloride 
kg kilo gram 
kHz kilo hearts (frequence) 
Kcond conditional stability constant 
Ktherm thermodynamic stability constant  
l liter 
LC50 lethal concentration at 50% 
logP partition-coefficient 
M molar 
MD Meniere‘s Disease 
MET channel mechanoelectrical transtuction channel 
Mg2+ magnesium ion 
MgSO4 magnesium sulfate 
mg milligram 
ml milliliter 
mm millimeter 
mmol millimol 
MMR Marc’s modified ringer solution 
MRI Magnetic Resonance Imaging 
mV millivolt 
n number 
Na+ sodium ion 
NaCl sodium chloride 
NaOH sodium hydroxide 
N.D. not determined 
ng nanogram 
nm nanometer 
NSF Nephrogenic systemic fibrosis 
PBS phosphate buffered saline 
pH 
decimal logarithm of the reciprocal of the hydrogen ion activity 
in a solution 
R rest / moiety 
RFU relative fluorescent unit 
SD standard deviation 
sec second 
T Tesla 
T1/2 Dissociation half-time at pH 1.0 and 25°C 
TRPV4 TRP vanilloid 4 channel 
VOR vestibular ocular reflex 
vs. versus 
x fold 
σ standard deviation 
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